UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: ~~September~~June 30, ~~2020~~2021


	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-35182

cid:image001.jpg@01CDF343.4BBAE3B0

AMPIO PHARMACEUTICALS, INC.

(~~www.ampiopharma.com~~)

(Exact name of registrant as specified in its charter)


Delaware	26-0179592
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

(Address of principal executive offices, including zip code)

(720) 437-6500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each ~~class:~~class	Trading Symbol	Name of each exchange on which registered:
Common Stock, par value $0.0001 per share	AMPE	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth ~~company~~company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☐	Accelerated Filer	☒☐

Non-Accelerated Filer	☐☒	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October 31, 2020,~~July 30, 2021, there were ~~185,055,000~~200,457,957 outstanding shares of ~~Common Stock,~~common stock, par value $0.0001 per share, of the registrant.

Table of Contents

AMPIO PHARMACEUTICALS, INC.

FOR THE QUARTER ENDED ~~SEPTEMBER~~JUNE 30, ~~2020~~2021

INDEX

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as forward-looking statements. All statements included or incorporated by reference in this report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment about the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by such statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “should,” “plan,” “potential,” “project,” “will,” “would” and other words of similar meaning, or the negatives of such terms or other variations. These include, but are not limited to, statements relating to the following:

●

projected operating or financial results, including anticipated cash flows used in operations;

●

expectations regarding clinical trials for Ampion, capital expenditures, research and development expenses and other payments;

●

our beliefs and assumptions relating to our liquidity position, including, but not limited to, our ability to obtain near-term additional financing;

●

our beliefs, assumptions and expectations about the regulatory approval pathway for Ampion including, but not limited to, our ability to obtain regulatory approval for Ampion in a timely manner, or at all; and

●

our ability to identify strategic partners and enter into beneficial license, co-development, collaboration or similar arrangements.

Any or all of our forward-looking statements may turn out to be wrong. They may be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:

●

our ability to continue as a going concern;

●

the fact that we have incurred significant losses since inception, expect to incur net losses for at least the next several years and may never achieve or sustain profitability;

●

our ability to fund our operations, including our ability to access sufficient funding through our “at-the-market” ~~offering;~~equity offering or through other equity or debt offerings;

●

~~the loss of~~our ability to retain key ~~management personnel upon whom we depend;~~employees, consultants, and advisors and to attract, retain and motivate qualified personnel;

●

the progress and results of clinical trials for Ampion and additional costs or delays associated therewith;

●

the significant competition in the search for a treatment for COVID-19;

●

our ability to enroll hospitalized patients in our Phase I and II trials of Ampion for the treatment of COVID-19 given the unplanned variability of the virus, vaccine rates and mutations in the virus in certain geographies;

●

our ability to receive regulatory approval for and sell the products that we are developing for the treatment of COVID-19;

●

our reliance on third parties to conduct our clinical trials resulting in costs or delays that prevent us from successfully commercializing Ampion;

●

competition for patients in conducting clinical trials, delaying product development and straining our limited financial resources;

●

the risk and costs associated with our decision to suspend enrollment in the Phase III clinical trial for treatment of severe Osteoarthritis of the Knee ~~(“OAK”)~~ due to considerations relating to the COVID-19 pandemic;

●

our ability to navigate the regulatory approval process in the U.S. and other countries, and our success in obtaining required regulatory approvals for Ampion on a timely basis;

●

our need to rely on third party manufacturers if we receive regulatory approval for Ampion but do not have redundant manufacturing capabilities;

●

commercial developments for products that compete with Ampion;

●

the actual and perceived effectiveness of Ampion, and how Ampion compares to competitive products;

Table of Contents

●

the rate and degree of market acceptance and clinical utility of Ampion or any of our other product candidates for which we receive marketing approval;

●

the possibility that, even if Ampion is approved for commercialization, the FDA may impose limitations on its use or reduce the approved indications on the product label;

●

expenses and costs we will incur to comply with FDA post-approval requirements if we, or our collaborators, obtain marketing approval for Ampion;

●

government restrictions on pricing reimbursement, as well as other healthcare payor cost-containment initiatives;

●

our ability to obtain approval to develop, manufacture and sell our products internationally;

●

our ability to realize the investment we made in our manufacturing facility if Ampion does not receive marketing approval;

●

adverse effects of the recent and ongoing COVID-19 pandemic;

●

the strength of our intellectual property protection, and our success in avoiding infringement of the intellectual property rights of others;

●

adverse developments in our research and development activities;

●

potential liability if any of our product candidates cause illness, injury or death, or adverse publicity from any such events;

●

our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required; and

~~Table of Contents~~

●

our expectations with respect to future licensing, partnering or other strategic activities.

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this report, including, but not limited to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on ~~February 21, 2020~~March 3, 2021 (the ~~“2019~~“2020 Annual Report”), particularly in the “Risk Factors” sections of each report, that could cause actual results or events to differ materially from the forward-looking statements that we make herein. Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement should be relied upon. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this report, except as otherwise required by applicable law.

This Quarterly Report on Form 10-Q includes trademarks for Ampion^®, which are protected under applicable intellectual property laws and are our property. Solely for convenience, our trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the ^® or ^TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and trade names.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

AMPIO PHARMACEUTICALS, INC.

Condensed Balance Sheets

(unaudited)


	September 30,		December 31,		June 30,		December 31,
	2020		2019		2021		2020

Assets
Current assets
Cash and cash equivalents	$	9,361,000	$	6,532,000	$	20,549,000	$	17,346,000
Prepaid expenses and other		1,475,000		1,718,000		2,358,000		1,147,000
Total current assets		10,836,000		8,250,000		22,907,000		18,493,000

Fixed assets, net		3,838,000		4,748,000		3,074,000		3,561,000
Right-of-use asset		870,000		1,003,000		728,000		824,000
Total assets	$	15,544,000	$	14,001,000	$	26,709,000	$	22,878,000

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable and accrued expenses	$	1,641,000	$	4,025,000	$	2,937,000	$	1,550,000
Lease liability-current portion		278,000		259,000		298,000		284,000
Total current liabilities		1,919,000		4,284,000		3,235,000		1,834,000

Lease liability-long-term		999,000		1,210,000		773,000		925,000
Warrant derivative liability		1,901,000		2,064,000		2,340,000		2,607,000
Total liabilities		4,819,000		7,558,000		6,348,000		5,366,000

Commitments and contingencies (Note 7)

Stockholders’ equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; NaN issued		—		—		—		—
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 183,938,000 as of September 30, 2020 and 158,645,000 as of December 31, 2019		18,000		16,000
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 200,070,419 as of June 30, 2021 and 193,378,996 as of December 31, 2020						20,000		19,000
Additional paid-in capital		206,618,000		191,060,000		228,091,000		218,020,000
Accumulated deficit		(195,911,000)		(184,633,000)		(207,750,000)		(200,527,000)
Total stockholders’ equity		10,725,000		6,443,000		20,361,000		17,512,000

Total liabilities and stockholders’ equity	$	15,544,000	$	14,001,000	$	26,709,000	$	22,878,000

The accompanying notes are an integral part of these financial statements.

Table of Contents

AMPIO PHARMACEUTICALS, INC.

Condensed Statements of Operations

(unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020

Operating expenses
Research and development	$	1,655,000	$	3,428,000	$	7,027,000	$	7,129,000	$	2,273,000	$	1,118,000	$	4,568,000	$	5,373,000
General and administrative		1,647,000		1,745,000		4,896,000		4,301,000		1,400,000		1,482,000		2,923,000		3,249,000
Total operating expenses		3,302,000		5,173,000		11,923,000		11,430,000		3,673,000		2,600,000		7,491,000		8,622,000

Other (expense) income
Other income (expense)
Interest income		0		8,000		12,000		53,000		1,000		0		2,000		12,000
Paycheck Protection Program funding		0		0		544,000		0
Paycheck Protection Program loan forgiveness										—		544,000		—		544,000
Derivative gain (loss)		7,000		(2,054,000)		163,000		(1,233,000)		116,000		(675,000)		267,000		156,000
Loss on disposal of asset		(73,000)		—		(73,000)		—
Total other (expense) income		(66,000)		(2,046,000)		646,000		(1,180,000)
Total other income (expense)										117,000		(131,000)		269,000		712,000

Net loss	$	(3,368,000)	$	(7,219,000)	$	(11,277,000)	$	(12,610,000)	$	(3,556,000)	$	(2,731,000)	$	(7,222,000)	$	(7,910,000)

Net loss per common share:
Basic	$	(0.02)	$	(0.05)	$	(0.07)	$	(0.10)	$	(0.02)	$	(0.02)	$	(0.04)	$	(0.05)
Diluted	$	(0.02)	$	(0.05)	$	(0.07)	$	(0.10)	$	(0.02)	$	(0.02)	$	(0.04)	$	(0.05)

Weighted average number of common shares outstanding:
Basic		178,622,000		142,208,000		168,062,000		122,895,000		196,179,371		166,392,893		195,785,398		162,723,309
Diluted		178,622,000		142,208,000		169,354,000		122,895,000		201,448,038		166,392,893		200,985,349		163,906,257

The accompanying notes are an integral part of these financial statements.

Table of Contents

AMPIO PHARMACEUTICALS, INC.

Condensed Statements of Stockholders’ Equity ~~(Deficit)~~

(unaudited)


				Additional				Total						Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders'
	Shares	Amount		Capital		Deficit		Equity (Deficit)
Balance at December 31, 2018	110,942,000	$	11,000	$	176,228,000	$	(171,003,000)	$	5,236,000

Issuance of common stock for services	136,000		0		60,000		0		60,000
Stock-based compensation, net of forfeitures	—		0		28,000		0		28,000
Warrants exercised, net	50,000		0		20,000		0		20,000
Net loss	—		0		0		(5,812,000)		(5,812,000)

Balance at March 31, 2019	111,128,000	$	11,000	$	176,336,000	$	(176,815,000)	$	(468,000)

Stock-based compensation, net of forfeitures	—		0		73,000		0		73,000
Warrants exercised, net	825,000		0		330,000		0		330,000
Issuance of common stock in connection with the "at-the-market" equity offering program	255,000		0		142,000		0		142,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program	—		0		(144,000)		0		(144,000)
Issuance of common stock in connection with public offering	30,000,000		3,000		11,997,000		0		12,000,000
Offering costs related to the issuance of common stock in connection with public offering	—		0		(1,243,000)		0		(1,243,000)
Net income	—		0		0		421,000		421,000

Balance at June 30, 2019	142,208,000	$	14,000	$	187,491,000	$	(176,394,000)	$	11,111,000

Stock-based compensation, net of forfeitures	—		0		246,000		0		246,000
Net loss	—		0		0		(7,219,000)		(7,219,000)

Balance at September 30, 2019	142,208,000	$	14,000	$	187,737,000	$	(183,613,000)	$	4,138,000
											Common Stock			Paid-in		Accumulated		Stockholders'
											Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2019	158,645,000		16,000		191,060,000		(184,633,000)		6,443,000		158,644,757	$	16,000	$	191,060,000	$	(184,633,000)	$	6,443,000

Issuance of common stock for services	136,000		0		80,000		0		80,000		136,236		0		80,000		0		80,000
Stock-based compensation, net of forfeitures	—		0		213,000		0		213,000		—		0		213,000		0		213,000
Issuance of common stock in connection with the "at-the-market" equity offering program	1,241,000		0		682,000		0		682,000		1,241,126		0		682,000		0		682,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program	—		0		(246,000)		0		(246,000)		—		0		(246,000)		0		(246,000)
Net loss	—		0		0		(5,179,000)		(5,179,000)		—		0		0		(5,179,000)		(5,179,000)

Balance at March 31, 2020	160,022,000	$	16,000	$	191,789,000	$	(189,812,000)	$	1,993,000		160,022,119	$	16,000	$	191,789,000	$	(189,812,000)	$	1,993,000

Stock-based compensation, net of forfeitures	—		0		64,000		0		64,000		—		0		64,000		0		64,000
Stock options exercised, net	1,000		0		0		0		0		1,314		0		0		0		0
Warrants exercised, net	250,000		0		100,000		0		100,000
Warrants exercised											250,000		0		100,000		0		100,000
Issuance of common stock in connection with the "at-the-market" equity offering program	13,069,000		1,000		7,230,000		0		7,231,000		13,068,517		1,000		7,230,000		0		7,231,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program	—		0		(314,000)		0		(314,000)		—		0		(314,000)		0		(314,000)
Net loss	—		0		0		(2,731,000)		(2,731,000)		—		0		0		(2,731,000)		(2,731,000)

Balance at June 30, 2020	173,342,000	$	17,000	$	198,869,000	$	(192,543,000)	$	6,343,000		173,341,950	$	17,000	$	198,869,000	$	(192,543,000)	$	6,343,000


Balance at December 31, 2020											193,378,996		19,000		218,020,000		(200,527,000)		17,512,000

Issuance of common stock for services											54,052		0		80,000		0		80,000
Stock-based compensation, net of forfeitures	—		0		477,000		0		477,000		—		0		166,000		0		166,000
Settlement of employee tax liability related to stock option exercise, net	3,000		0		(2,000)		0		(2,000)
Stock options exercised, net											129,500		0		33,000		0		33,000
Shares held back in settlement of tax obligation and exercise cost											(28,562)		0		(40,000)		0		(40,000)
Warrants exercised, net	1,188,000		0		365,000		0		365,000		306,705		0		114,000		0		114,000
Issuance of common stock in connection with the "at-the-market" equity offering program	9,405,000		1,000		7,222,000		0		7,223,000		1,848,437		0		2,705,000		0		2,705,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program	—		0		(313,000)		0		(313,000)		—		0		(126,000)		0		(126,000)
Net loss	—		0		0		(3,368,000)		(3,368,000)		—		0		0		(3,667,000)		(3,667,000)

Balance at September 30, 2020	183,938,000	$	18,000	$	206,618,000	$	(195,911,000)	$	10,725,000
Balance at March 31, 2021											195,689,128	$	19,000	$	220,952,000	$	(204,194,000)	$	16,777,000

Stock-based compensation, net of forfeitures											—		0		67,000		0		67,000
Stock options exercised, net											314,162		0		127,000		0		127,000
Shares held back in settlement of tax obligation and exercise cost											(28,802)		0		0		0		0
Warrants exercised, net											29,158		0		0		0		0
Issuance of common stock in connection with the "at-the-market" equity offering program										��	4,066,773		1,000		7,266,000		0		7,267,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program											—		0		(321,000)		0		(321,000)
Net loss											—		0		0		(3,556,000)		(3,556,000)

Balance at June 30, 2021											200,070,419	$	20,000	$	228,091,000	$	(207,750,000)	$	20,361,000

The accompanying notes are an integral part of these financial statements.

Table of Contents

AMPIO PHARMACEUTICALS, INC.

Condensed Statements of Cash Flows

(unaudited)


	Nine Months Ended September 30,				Six Months Ended June 30,
	2020		2019		2021		2020

Cash flows from operating activities
Cash flows used in operating activities
Net loss	$	(11,277,000)	$	(12,610,000)	$	(7,222,000)	$	(7,910,000)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation, net of forfeitures		754,000		347,000		233,000		277,000
Depreciation and amortization		885,000		975,000		568,000		591,000
Loss on disposal of fixed asset		73,000		0
Paycheck Protection Program funding that offsets qualified expenses		(544,000)		0
Paycheck Protection Program loan forgiveness						0		(544,000)
Issuance of common stock for services		80,000		60,000		80,000		80,000
Derivative (gain) loss		(163,000)		1,233,000
Derivative gain						(267,000)		(156,000)
Changes in operating assets and liabilities
Decrease (increase) in prepaid expenses and other		243,000		(1,390,000)
(Decrease) increase in accounts payable and accrued expenses		(2,385,000)		805,000
Increase in prepaid expenses and other						(1,211,000)		(229,000)
Increase (decrease) in accounts payable and accrued expenses						1,386,000		(1,758,000)
Decrease in lease liability		(59,000)		(52,000)		(42,000)		(38,000)
Proceeds received under the Paycheck Protection Program		544,000		0		0		544,000
Net cash used in operating activities		(11,849,000)		(10,632,000)		(6,475,000)		(9,143,000)

Cash flows used in investing activities
Purchase of fixed assets		(48,000)		(14,000)		(81,000)		0
Net cash used in investing activities		(48,000)		(14,000)		(81,000)		0

Cash flows from financing activities
Proceeds from sale of common stock in connection with "at-the-market" equity offering program		15,136,000		142,000		9,972,000		7,913,000
Costs related to sale of common stock in connection with the "at-the-market" equity offering program		(873,000)		(144,000)		(447,000)		(560,000)
Proceeds from sale of common stock in connection with the public offering		0		12,000,000
Costs related to sale of common stock in connection with the public offering		0		(1,243,000)
Proceeds from warrant exercises		465,000		350,000
Settlement of employee tax liability related to stock option exercise, net		(2,000)		0
Proceeds from warrant and stock option exercises, net						234,000		100,000
Net cash provided by financing activities		14,726,000		11,105,000		9,759,000		7,453,000

Net change in cash and cash equivalents		2,829,000		459,000		3,203,000		(1,690,000)

Cash and cash equivalents at beginning of period		6,532,000		7,585,000		17,346,000		6,532,000
Cash and cash equivalents at end of period	$	9,361,000	$	8,044,000	$	20,549,000	$	4,842,000

Non-cash transactions:
Commercial insurance premium financing agreement	$	1,347,000	$	0	$	1,016,000	$	1,347,000
Initial lease liability arising from the adoption of ASC 842		0		1,704,000
Initial recognition of right-of-use asset arising from the adoption of ASC 842		0		1,168,000

The accompanying notes are an integral part of these financial statements.

Table of Contents

AMPIO PHARMACEUTICALS, INC.

Notes to Condensed Financial Statements

(unaudited)

Note 1 – The Company and Summary of Significant Accounting Policies

Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles ~~generally accepted~~(“GAAP”) in the United States ~~(“GAAP”)~~ for interim financial information and with the instructions of the SEC on Quarterly Reports on Form 10-Q and Article 8 of Regulation S-X. Accordingly, such financial statements do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of the Company for the periods presented.

These financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, ~~2019~~2020 included in the Company’s ~~2019~~2020 Annual Report. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The information as of and for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 is unaudited. The balance sheet at December 31, ~~2019~~2020 was derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.

Impact of Global Pandemic

In January 2020, the Secretary of Health and Human Services (“HHS”) declared a public health emergency and the World Health Organization (“WHO”) announced a global health emergency because of ~~a new strain of~~ the novel ~~coronavirus~~Coronavirus Disease 2019 (“COVID-19”). In March 2020, the WHO declared the outbreak of COVID-19, a global pandemic. Since the declaration of the outbreak, COVID-19 has adversely impacted and continues to ~~significantly affect~~adversely impact the United States and global economies. In April 2020, and pursuant to the U.S. Food and Drug Administration (“FDA”), independent Safety Monitoring Committee (“SMC”), and ~~regulatory~~ Institutional Review Board guidance covering ongoing clinical trials in the presence of the COVID-19 pandemic, the Company and the clinical research organization (“CRO”) paused all ongoing conduct associated with the Phase III clinical trial (the “AP-013 study”) of Ampion for the treatment of ~~OAK, also known as~~Osteoarthritis of the ~~“AP-013 study”~~Knee (“OAK”). ~~Due~~In March 2021, the Company submitted a detailed proposal to the ~~increases~~FDA in ~~reported COVID-19 cases,~~response to the ~~Company has determined that~~FDA’s guidance regarding the AP-013 study will remain paused. However, the FDA recently provided guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were adversely impacted by the pandemic. The Company is reviewing this guidance and continues to have ongoing discussions with the CRO to determine the best approach forstatus of the AP-013 study. ~~Since~~In April 2021, the ~~filing of~~Company received a response to the proposal from the FDA, which provides guidance and flexibility on how to maintain the Special Protocol Assessment (“SPA”), while allowing the Company to evaluate and consider several paths for moving forward. In May 2021, the FDA issued updated statistical guidance for the industry. At this time, the Company is evaluating its ~~Form 10-Q covering~~options to analyze the ~~three-month period ending~~clinical trial data from the AP-013 study.

In addition, since June ~~30,~~ 2020, the Company has ~~been conducting~~commenced several clinical trials ~~related~~ to ~~potential~~determine the safety and efficacy for new applications of Ampion (i.e., inhaled and intravenous) related to COVID-19 infection. Given the continued evolution of the COVID-19 ~~infection. The outbreak has~~pandemic and ~~may continue to spread, which could materially impact~~the related complexities and uncertainties associated with the additional variants, the Company’s business operations could be significantly impacted and, in addition, ~~those~~the business operations of third parties on which the Company relies, including organizations that conduct clinical trials and key suppliers which provide the raw materials for manufacturing Ampion for the ongoing clinical ~~trials.~~trials could also be impacted. The full extent of the potential ~~impacts~~adverse impact on the Company’s business operations and related current and future product development, including, but not limited to, clinical trials, financing activities and the overall impact on the United States and the global economy will depend on future developments related to the pandemic, which cannot be predicted due to the uncertain nature of the continued COVID-19 pandemic, government mandated shut downs, and its adverse effects, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. These effects could have a material adverse impact on the Company’s business, operations, financial condition and results of operations.at this time.

Table of Contents

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the three and six months ended ~~September~~June 30, ~~2020,~~2021, and as consistent with prior reporting periods, the Company maintained balances in excess of federally insured limits.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Significant items subject to such estimates and assumptions primarily include the Company’s projected ~~future~~ liquidity and resulting going concern position, ~~warrant derivative liability~~clinical trial accrual and ~~related periodic gains and losses, stock-based compensation,~~ the projected useful lives and potential impairment of fixed ~~assets, and the valuation allowance related to deferred tax~~ assets. The Company develops these estimates using its judgment based upon the facts and circumstances known at the time.

Adoption of Recent Accounting Pronouncements

The Company has not adopted any recent accounting pronouncements during the six months ended June 30, 2021.

Recent Accounting Pronouncements

In August ~~2018,~~2020, the ~~FASB~~Financial Accounting Standards Board (“FASB”) issued ASU ~~2018-13,~~2020-06, “~~Fair Value Measurement - Disclosure Framework (Topic 820)~~Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity”. The updated guidance ~~modified~~is part of the ~~disclosure requirements on fair value measurements.~~FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. Consequently, more convertible debt instruments will be reported as single liability instruments with no separate accounting for embedded conversion features. The ASU 2020-06 also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. In addition, ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The updated guidance is effective for fiscal years beginning after December 15, ~~2019, including~~2023, and interim ~~reporting~~ periods within those fiscal ~~years.~~years, with early adoption permitted for periods beginning after December 15, 2020. The Company ~~adopted~~is currently evaluating the impact of ASU ~~2018-13 during the first quarter of 2020 and the adoption of this guidance did not have a material impact~~2020-06 on the Company’s financial statements.

~~Recent Accounting Pronouncements~~

~~The Company reviewed the recent accounting pronouncements and determined that none of the recent accounting pronouncements were applicable.~~

This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Note 2 - Going Concern

As of and for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company had cash and cash equivalents of ~~$9.4~~$20.5 million and a net loss of ~~$11.3~~$7.2 million, respectively. The net loss is primarily attributable to operating expenses of ~~$11.9~~$7.5 million, partially offset by the ~~receipt of Paycheck Protection Program (“PPP”) proceeds of $0.5 million (see~~ ~~Note 6~~~~) and~~ non-cash derivative gain of ~~$0.2~~$0.3 million (see Note 9). The Company used ~~net cash in~~$6.5 million to fund its business operations of ~~$11.9~~ ~~million~~ for the ~~nine months~~six-month period ended ~~September~~June 30, ~~2020~~2021 and ended the ~~quarter~~period with an accumulated deficit and stockholders’ equity of ~~$196.0~~$207.8 million and ~~$10.7~~$20.4 million, respectively. ~~In addition, as~~As a clinical stage biopharmaceutical company, the Company has not generated any operating revenues or profits since the inception of business operations. In addition, the Company is subject to ~~date.~~all of the risks and uncertainties typically associated with biopharmaceutical companies that

Table of Contents

devote substantially all of their efforts and resources to research and development, as well as clinical trials, and do not yet have commercialized products. These existing and projected on-going factors continue to raise substantial doubt about the Company’s ability to continue as a going concern.

In February 2020, the Company entered into a Sales Agreement (“Sales Agreement”) with 2 agents to implement an “at-the-market” (“ATM”) equity offering program under which the Company, from time to time and at its sole discretion, may issue and sell

~~Table of Contents~~

~~from time to time~~ shares of its authorized common stock. During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company sold shares pursuant to the ATM equity offering program, which yielded gross proceeds of ~~$15.1~~approximately $10.0 million, ~~(see~~ ~~Note 10~~~~). In October 2020, the Company received additional gross proceeds of $1.0 million from the sale of 1.1 million shares of common stock under the ATM equity offering program,~~ which was offset by offering related costs of ~~$40,000.~~$0.4 million (see Note 10).

The Company has prepared an updated projection covering the period from ~~October~~July 1, ~~2020~~2021 through ~~September 30, 2021~~August 31, 2022 based on the requirements of ASC 205-40, “Going Concern”, which reflects cash requirements for fixed, recurring base level business expenses such as payroll, legal and accounting, patents and overhead, and incremental costs supporting the existing and projected clinical development programs. The Company continues to assess the impact of the COVID-19 pandemic ~~including the increase in COVID-19 cases in the United States~~ and the impact that it may have on the ~~AP-013 study~~Company’s current and ~~any new studies related to COVID-19, and, as such, is not currently in a position to project the required liquidity needs for completion of these~~projected future studies. The Company anticipates using the ATM equity offering program to raise additional funds in the near term, as needed, while also considering supplementing the funds raised with separate ~~private/~~private or public equity offering(s). Based on the Company’s current cash position, projection of ~~operations~~operating expenses, current and ~~expected access to~~projected capacity under the ATM and/or other equity financing opportunities, the Company believes it will have sufficient liquidity to fund operations through the ~~third~~fourth quarter of ~~2021.~~2022. This projection is based on many assumptions that may prove to be incorrect. ~~For example, despite~~Despite the ~~historically successful~~prior access and use of the ATM equity offering program due to the inherent uncertainties associated with raising capital in the public markets and the fact that the ATM equity offering program is not deemed a fixed and determinable committed source of liquidity, the Company’s management is unable to conclude that it is probable that future capital will be available to satisfy future liquidity needs in a manner ~~that will be~~to provide sufficient ongoing liquidity to ~~fund operations.~~the Company, the ATM is not considered to represent a source of committed capital. As such, it is possible that the Company could exhaust its available cash and cash equivalents earlier than presently anticipated. In addition, asgiven the ~~global~~ongoing continued uncertainty of the COVID-19 pandemic, ~~continues to rapidly evolve,~~ its effect on the Company’s business operations and ability to raise capital ~~through the ATM equity offering program, or otherwise,~~ remains ~~highly~~ uncertain and subject to change. ~~The~~While the Company believes that the studies currently being conducted will be successful, the Company expects to ~~seek~~raise additional capital ~~investments~~ in both the near and long-term to enable it to support its business operations, including specifically (i) clinical development of Ampion, (ii) Biologics License Application (“BLA”) preparation and submission, (iii) existing base business operations and (iv) commercial development activities for Ampion. The Company will continue to closely monitor and evaluate the overall capital markets to determine the appropriate timing and funding level for ~~sourcing~~any such capital raising activities, which will primarily depend on stock price and existing market conditions relative to the timing of the Company’s liquidity needs. However, the Company cannot ~~give~~currently provide any assurance that it will be successful in satisfying its future liquidity needs in a manner that will be sufficient to fund its base level of operations and any incremental expenses related to the further development of Ampion for OAK, therapeutic treatment of COVID-19 and other ~~indications.~~indications as they arise.

The accompanying unaudited interim financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities, which adjustments may be necessary in the future should the Company be unable to continue as a going concern.

Note 3 – Prepaid Expenses and Other

Prepaid expenses and other balances as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 are as follows:


	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020

Deposits					$	1,236,000	$	266,000
Unamortized commercial insurance premiums	$	970,000	$	502,000		981,000		627,000
Deposits		214,000		1,162,000
BLA consulting services refund		182,000		-
Annual maintenance service contracts						63,000		—
Receivable		14,000		14,000		30,000		185,000
Other		95,000		40,000		48,000		69,000
Total prepaid expenses and other	$	1,475,000	$	1,718,000	$	2,358,000	$	1,147,000

Table of Contents

Note 4 – Fixed Assets

Fixed assets are recorded based on acquisition cost and, once placed in service, are depreciated onutilizing the straight-line method over their estimated economic useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease term. Fixed assets, net of accumulated depreciation and amortization, consist of the following:

Estimated

Weighted Average

Net Book Value

Net Book Value

Useful Lives

Remaining Useful

December 31,

Accumulated

September 30,


in Years

Lives in Years

2019

Additions

Disposals

Depreciation

2020

Leasehold improvements

10

4

$
2,850,000

$
—

$
—

$
(450,000)

$
2,400,000
Manufacturing facility/clean room

3 - 8

3

1,550,000

9,000

(73,000)

(370,000)

1,116,000
Lab equipment and office furniture

5 - 8

3

348,000

39,000

—

(65,000)

322,000
Fixed assets, net

$
4,748,000

$
48,000

$
(73,000)

$
(885,000)

$
3,838,000


	Estimated
	Useful Lives	June 30,		December 31,
	(in Years)	2021		2020

Leasehold improvements	10	$	1,950,000	$	2,250,000
Manufacturing facility/clean room	3 - 8		834,000		998,000
Lab equipment and office furniture	5 - 8		290,000		313,000
Fixed assets, net		$	3,074,000	$	3,561,000

Depreciation and amortization expense for the respective periods is as follows:

Three Months Ended September 30,

Nine Months Ended September 30,


2020

2019

2020

2019


Depreciation and amortization expense

$
294,000

$
320,000

$
885,000

$
975,000


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020

Depreciation and amortization expense	$	274,000	$	296,000	$	568,000	$	591,000

Note 5 – Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 are as follows:


	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020

Accounts payable	$	398,000	$	151,000	$	170,000	$	186,000
Commercial insurance premium financing agreement		721,000		21,000
Clinical trials		225,000		3,288,000		1,525,000		558,000
Commercial insurance premium financing						808,000		386,000
Professional fees		181,000		317,000		380,000		267,000
Other		116,000		176,000		54,000		153,000
Accrued incentive compensation		—		72,000
Accounts payable and accrued expenses	$	1,641,000	$	4,025,000	$	2,937,000	$	1,550,000

Note 6 – Paycheck Protection Program

In response to the COVID-19 pandemic, the PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (“SBA”). Companies who met the eligibility requirements set forth by the PPP could qualify for PPP loans provided by local lenders, which supports payroll, rent and utility expenses (“qualified expenses”). If the loan proceeds are fully utilized to pay qualified expenses over the covered period, as further defined by the PPP, the full principal amount of the PPP loan may qualify for loan forgiveness, subject to potential reduction based on the level of full-time employees maintained by the organization during the covered period as compared to a baseline period.

In April 2020, the Company received proceeds of $544,000 ~~under the PPP provided by~~via a loan from KeyBank National Association (the “Lender”)~~. Based on~~ that was issued under the ~~term~~Paycheck Protection Program (the “PPP”) established under the Coronavirus Aid, Relief and ~~conditions of the loan agreement, the~~Economic Security Act. The term of the PPP loan is two years with an annual interest rate of 1.0% and principal and interest payments will be deferred for the first six months of the loan term, which ~~has been~~was subsequently updated ~~according to~~in accordance with the Paycheck Protection Program Flexibility Act of 2020.

In October 2020, ~~(“Flexibility Act”~~the Company submitted its PPP loan forgiveness application, requesting forgiveness of the full principal amount of its PPP loan. In May 2021, the Company received notification from the Lender that the Small Business Administration (the “SBA”). had authorized full forgiveness of the PPP loan. In July 2021, the Company received notification from the Lender that the SBA submitted, and the Lender has received, proceeds representing the full pay-off of the loan balance. As such, the Company’s loan balance is considered to be paid off in full.

Table of Contents

In June 2020, the Flexibility Act was signed into law, which amended the CARES Act. The Flexibility Act changed key provisions of the PPP, including, but not limited to, (i) provisions relating to the maturity of PPP loans, (ii) the deferral period covering of PPP loan payments and (iii) the process for measurement of loan forgiveness. More specifically, the Flexibility Act provides a minimum maturity of five years for all PPP loans made on or after June 5, 2020, the date of the enactment of the Flexibility Act, and permits lenders and borrowers to extend the maturity date of earlier PPP loans by mutual agreement. As of the date of this filing, the Company has not approached the Lender to request an extension of the maturity date from two years to five years. The Flexibility Act also provides that if a borrower does not apply for forgiveness of a loan within 10 months after the last day of the measurement period (the “covered period”), the PPP loan is no longer deferred and the borrower must begin paying principal and interest. Therefore, the Company’s deferral period for principal and interest payments was updated from six months according to the terms and conditions of the loan agreement to ten months. In addition, the Flexibility Act extended the length of the covered period from eight weeks to 24 weeks from receipt of proceeds, while allowing borrowers that received PPP loans before June 5, 2020 to determine, at their sole discretion, a covered period of either eight weeks or 24-weeks.

After reviewing the applicable terms and conditions of the Flexibility Act, the Company has elected to extend the length of the covered period from eight weeks to the lesser of (i) the period whereby qualified expenses equal loan proceeds or (ii) 24 weeks. The Company has performed initial calculations of its PPP loan forgiveness eligibility according to the terms and conditions of the SBA’s Loan Forgiveness Application (Revised June 16, 2020) and, based on such calculations, expects that the PPP loan will be forgiven in full over a period of less than 24 weeks. In addition, the Company has determined that it is probable that the Company will meet all the conditions of the PPP loan forgiveness program. As such, the Company has determined that the PPP loan should be accounted for as a government grant which analogizes with International Accounting Standards (“IAS”) 20, ~~Accounting for Government Grants and Disclosure of Government Assistance~~. Under the provisions of IAS 20, “a forgivable loan from government is treated as a government grant when there is reasonable assurance that the entity will meet the terms for forgiveness of the loan.” IAS 20 does not define “reasonable assurance”, however, based on certain interpretations, it is analogous to “probable” in GAAP under FASB ASC 450-20-20, which is the definition the Company has applied to its expectations of the Company’s eligibility for PPP loan forgiveness. In addition, in accordance with the provisions of IAS 20, government grants shall be recognized in profit or loss on a systematic basis over the periods in which the Company recognizes costs for which the grant is intended to compensate (i.e. qualified expenses). Therefore, the Company recognized PPP funding during the periods when qualified expenses were incurred. The balance and activity related to the PPP loan is as follows as of September 30, 2020:

September 30, 2020

PPP loan proceeds

$
544,000
Qualified expenses eligible for forgiveness

(544,000)
PPP loan balance

$
—

In October 2020, the Company submitted the PPP loan forgiveness application, which has been approved by the Lender. In accordance with the terms and conditions of the Flexibility Act, the Lender has 60 days from receipt of the completed application to issue a decision to the SBA. If the Lender determines that the borrower is entitled to forgiveness of some or all of the amount applied for under the statue and applicable regulations, the Lender must request payment from the SBA at the time the Lender issues its decision to the SBA. The SBA will, subject to any SBA review of the loan or loan application, remit the appropriate forgiveness amount to the Lender, plus any interest accrued through the date of payment, not later than 90 days after the Lender issues its decision to the SBA. Although the Company believes it is probable that the PPP loan will be forgiven, the Company cannot currently provide any objective assurance that it will obtain forgiveness in whole or in part.

Pursuant to the Flexibility Act, the Company’s PPP loan agreement will be amended in the event that no amount or less than all of the PPP loan is forgiven. In addition, starting in August 2021, the Company will be required to make principal and interest payments totaling $23,000 per month or an adjusted amount based on the loan amendment over the remaining term of the PPP loan until such time as the loan is fully settled. The Company may prepay the PPP loan at any time without penalty and the loan agreement evidencing the PPP loan contains customary events of default relating to, among other things, payment defaults, or breaches of representations and warranties, or other provisions of the loan

~~Table of Contents~~

agreement. The occurrence of an event of default may trigger an acceleration of the maturity date for all amounts outstanding, collection of all amounts owing from the Company and/or the Lender filing suit and obtaining a judgment against the Company.

Note 7 - Commitments and Contingencies

Commitments and contingencies are described below and summarized by the following table:

Total (1)

2020

2021

2022

2023

2024

Thereafter
Key clinical research trial obligations

$
2,915,000

$
675,000

$
2,240,000

$
0

$
0

$
0

$
0
BLA consulting services

1,143,000

—

457,000

686,000

0

0

0
Statistical analysis and programming consulting services

318,000

30,000

288,000

0

0

0

0
Employment agreements

1,478,000

216,000

783,000

466,000

13,000

0

0
Commercial insurance premium financing agreement

721,000

474,000

247,000

0

0

0

0

$
6,575,000

$
1,395,000

$
4,015,000

$
1,152,000

$
13,000

$
0

$
0

~~(1)~~

Not included in the commitments and contingencies table above are the monthly principal and interest payments of $23,000 that would be due beginning in August 2021 under the PPP loan if it is not forgiven by the SBA (see ~~Note 6~~).


	Total		2021		2022		2023		2024		2025		Thereafter
Key clinical research trial obligations	$	3,896,000	$	2,768,000	$	1,128,000	$	0	$	0	$	0	$	0
Employment agreements		830,000		351,000		466,000		13,000		0		0		0
Commercial insurance premium financing agreement		808,000		539,000		269,000		0		0		0		0
Statistical analysis and programming consulting services		326,000		163,000		163,000		0		0		0		0
	$	5,860,000	$	3,821,000	$	2,026,000	$	13,000	$	0	$	0	$	0

Key Clinical Research Trial Obligations

Osteoarthritis of the Knee

AP-013 study

In ~~March 2019,~~December 2020, the Company entered into aan initial contract with a CRO in connection with the AP-013 study totaling $6.2 million and covering an initial clinical trial size of 724 patients, which was increased by $4.1 million in January 2020 as a result of an increase in the number of participating patients to 1,034, resulting in the CRO contract commitment totaling $10.3 million. In April 2020, and pursuant to the FDA guidance covering ongoing clinical trials in the presence of the COVID-19 pandemic, the Company and the CRO paused all ongoing conduct associated with the AP-013 study. Increases in COVID-19 cases across certain regions of the United States continue to be reported on a consistent basis. Due to the continued increase in reported cases, the Company has determined that the AP-013 study will remain paused. However, the FDA recently provided guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were adversely impacted by the pandemic. The Company is reviewing this guidance and continues to have ongoing discussions with the CRO to determine the best approach for the AP-013 study.

From the inception of this contract through September 30, 2020, the Company incurred and accrued cumulative costs totaling $8.2 million against the contract. This contract had an outstanding obligation for future costs and services totaling $2.1 million as of September 30, 2020. However, this obligation assumes that the Company will continue the AP-013 study at the same point the study was paused, and that the completion of the study will be consistent with the parameters as contained in the existing contract, which may not be the case. The Company continues to explore all viable options to enable it to complete the AP-013 study; however, it is possible that the COVID-19 pandemic may prevent completion of the AP-013 study at this time or at all. Due to the uncertainty resulting from the COVID-19 pandemic, the future contractual commitment amount relatedreference to the AP-013 study ~~may change.~~database totaling $1.4 million. The ~~following table provides~~contractual provisions required a retainer of $315,000, which will be applied to future study expenses as further ~~detail~~defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the ~~Company’s current contractual obligations for~~retainer. In March 2021, the ~~conduct~~Company submitted a detailed proposal to the FDA in response to the FDA’s guidance regarding the status of the AP-013 study, which ~~does~~

~~Table~~was paused as a result of ~~Contents~~

~~not reflect any changes related~~the COVID-19 pandemic. In April 2021, the Company received a response to the ~~potential impact~~proposal from the FDA. In May 2021, the FDA issued updated statistical guidance for the industry. At this time, the Company is evaluating its options to analyze the clinical trial data from the AP-013 study. The Company had an outstanding future contractual commitment of ~~COVID-19,~~$382,000 (net of deposit) as ~~such impacts are unknown and cannot be reasonably estimated at the date~~ of ~~this filing:~~June 30, 2021.

September 30, 2020

Original contract (based on 724 patients)

$
6,180,000
Amendment to contract (based on 1,034 patients)

4,075,000
Total contract

$
10,255,000

Initial deposit (included in original contract amount)

$
861,000
Amendment to deposit

699,000
Expenses incurred applied to deposit

(1,386,000)
Remaining deposit (applied to future expenses)

$
174,000

Expenses incurred/accrued (includes expenses applied to deposit)

$
8,182,000

Total future commitment

$
2,073,000

Inhaled treatment for COVID-19 patients

AP-018 study and AP-019 study

In ~~May~~March 2021, the Company entered into a contract with a CRO totaling $318,000 in reference to a Phase I study for at-home treatment utilizing inhaled Ampion to treat patients with Post-Acute Sequelae of SARS-CoV-2 infection (“PASC”) commonly referred to as “Long-COVID”, or prolonged respiratory symptoms due to COVID-19 (the “AP-018 study”). The contractual provisions required an initial retainer of $105,000, which will be applied to future study expenses as further defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. The Company had an outstanding future contractual commitment of $130,000 (net of deposit) as of June 30, 2021.

In June 2021, the Company entered into a contract with a CRO totaling $2.5 million in reference to a multicenter Phase II clinical trial, using inhaled Ampion in the treatment of respiratory distress due to COVID-19 (the “AP-019 study”). The contractual provisions required an initial retainer of $300,000, which will be applied to future study expenses as further defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. The Company had an outstanding future contractual commitment of $2.2 million (net of deposit) as of June 30, 2021.

Intravenous (“IV”) treatment for COVID-19 patients

AP-017 study

In December 2020, the Company entered into a contract with a CRO totaling $1.8 million in ~~connection with~~reference to a pre-clinical inhaled safety study for Ampion totaling $207,000. In August 2020, the Company finalized contract negotiations to increase the contract to $250,000 as a result of additional pre-study work and reporting. In September 2020, the safety study was completed and, as such, the Company had no outstanding future commitment as of September 30, 2020. The data from the safety study was submitted to the FDA to support the Investigational New Drug (“IND”) application covering inhaled Ampion treatment for COVID-19 patients, which was granted in September 2020.

In September 2020, the Company entered into a contract with a CRO in connection with the FDA approved IND application covering inhaled Ampion treatment for COVID-19 infected patients hospitalized for respiratory distress (the “AP-014 study”) totaling $836,000. The Company expects to commence the AP-014 study during the fourth quarter of fiscal 2020 and, as such, had an outstanding future commitment of $836,000 as of September 30, 2020.

In October 2020, the Company entered into a contract with a regional hospital group in connection with the FDA approved IND application for the AP-014 study totaling $30,000. As noted above, the Company expects to commence the AP-014 study during the fourth quarter of fiscal 2020.

~~Intravenous (“IV”) treatment for COVID-19 patients~~

~~In June 2020, the Company entered into a contract with a CRO in connection with the FDA approved IND application covering~~multicenter Phase II clinical trial utilizing IV Ampion ~~treatment for COVID-19 patients (the “AP-016 study”) totaling $43,000. In September 2020, the AP-016 study was completed. However, the Company will continue to monitor the patients enrolled~~ in the ~~AP-016 study for a 90-day period subsequent to the completion~~treatment of ~~the study and costs are expected to be minimal during this period.~~

In July 2020, the Company entered into a contract with a regional hospital group in connection with the FDA approved IND application for the AP-016 study totaling $50,000. As noted above, the Company completed the AP-016 study in September 2020 and, as such, had 0 outstanding future commitment as of September 30, 2020.

~~BLA Consulting Services~~

In March 2018, the Company entered into a BLA consulting services agreement for $1.2 million. This contract required a deposit, of which $182,000 was funded and recorded within the “prepaid expenses and other” line item on the balance sheet. In June 2020, the Company finalized contract negotiations to increase the contract by a nominal amount to incorporate the review of the IND applications for inhaled and IV Ampion treatment. In September 2020, the Companypatients suffering from complications arising from COVID-

1513

Table of Contents

~~finalized~~19 (the AP-017 study”). The contractual provisions required a retainer of $345,000, which will be applied to future study expenses as further defined by the contract. The contract ~~negotiations~~currently accounts for 120 patients; however, based on the revised protocol, the number of patients has increased to ~~provide a refund of the deposit totaling $182,000 due to the pause of the AP-013 study and the delay in filing of the BLA.~~200. The Company is ~~required~~in ongoing discussions with the CRO to ~~provide a deposit totaling $364,000 once~~amend the ~~work commences related~~contractual amount to account for the ~~preparation~~additional patients expected to be enrolled. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the ~~related BLA for Ampion.~~ retainer.The Company had ~~incurred cumulative costs totaling $79,000 against this contract and, as such, had~~an outstanding future ~~obligations totaling $1.1~~contractual commitment of $1.2 million (net of deposit) as of ~~September~~June 30, 2020, which will be settled at such time future services are provided to the Company primarily related to the development and filing of the Ampion BLA. Given the uncertainty surrounding the COVID-19 pandemic and the resulting impact on the AP-013 study, at the date of this filing, the Company estimates the incurrence of the remaining costs associated with the preparation of the BLA filing will be postponed until late fiscal 2021, if not later.

~~Statistical Analysis and Programming Consulting Services~~

In May 2019, Ampio entered into a statistical analysis and programming consulting services agreement for $578,000. As of September 30, 2020, the Company had incurred cumulative costs totaling $260,000 against the contract and, as such, had an outstanding obligation of $318,000.2021.

Employment Agreements

On December 14, 2019, the Company entered into a ~~new~~ three-year employment agreement with Mr. Macaluso, Chief Executive Officer, which became effective January 10, 2020, immediately following the expiration of his prior employment agreement. The ~~new~~ employment agreement provides for an annual salary of $300,000 and term ending January 10, 2023, subject to certain automatic renewal provisions.

On September 16, 2019, the Company entered into a ~~new~~ two-year employment agreement with Ms. Cherevka, Chief Operating Officer, which by its terms cancelled the previous employment agreement on such date. The ~~new~~ employment agreement provides for an annual salary of $280,000 and a term ending September 16, 2021, subject to certain automatic renewal provisions.

The Company entered into an employment agreement with Mr. Daniel Stokely, Chief Financial Officer, on July 9, 2019, which provided for an annual salary of $285,000 and a term beginning July 31, 2019 and lasting for three years, subject to certain automatic renewal provisions. The employment agreement, as amended in July 2020, allowed for reimbursement of reasonable commuting and relocation expenses, including the employee portion of taxes, for up to one year. The commuting and relocation expenses were substantially incurred as of September 30, 2020 with the residual expected to be incurred during the fourth quarter of fiscal 2020.

Amounts noted above do not assume the continuation of employment beyond the contractual terms of each employee’s existing employment agreements.

Commercial Insurance Premium Financing Agreement

In ~~July 2020,~~June 2021, the Company entered into an insurance premium financing agreement for ~~$1.0~~$0.9 million, with a term of nine months and an annual interest rate of ~~3.37%~~3.57%. Under the terms and provisions of the agreement, the Company will be required to make principal and interest payments totaling ~~$116,000~~$82,000 per month over the remaining term of the agreement. The outstanding obligation as of ~~September~~June 30, ~~2020~~2021 was ~~$683,000,~~$734,000, which will be paid in full by March ~~2021.~~2022. In addition, as of ~~September~~June 30, ~~2020,~~2021, the Company had a remaining balance of ~~$38,000~~$74,000 related to annual insurance premiums payable to the Company’s insurance broker, which will be paid in full by March 2022.

Statistical Analysis and Programming Consulting Services

In May 2019, the Company entered into a statistical analysis and programming consulting services agreement for $578,000. As of June ~~2021.~~30, 2021, the Company had incurred cumulative costs totaling $252,000 against the contract and, as such, had an outstanding obligation of $326,000, which is expected to be settled by fiscal 2022.

Facility Lease

In December 2013, the Company entered into a 125-month non-cancellable operating lease for office space and a manufacturing facility. The effective date of the lease was May 1, 2014. The initial base rent of the lease was $23,000 per month. The total base rent over the term of the lease is approximately $3.3 million, which includes rent abatements and leasehold incentives. The Company adopted the FASB issued ASC 842, “Leases (Topic 842)” effective January 1, 2019. With the adoption of ASC 842, the Company recorded an operating right-of-use (“ROU”) asset and an operating lease liability on its balance sheet. The ROU asset represents the Company’s right to use the underlying asset for the

~~Table of Contents~~

lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. ROU lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s lease does not provide an implicit rate, the Company used an estimated incremental borrowing rate of 5.75% based on the information available at the commencement date in

Table of Contents

determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. The lease liability is classified both as current orin part and long-term in part on the balance ~~sheet.~~sheet based on the projected settlement of the liability.

The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability ~~presented in~~disclosed on the balance sheet as of ~~September~~June 30, ~~2020:~~2021:


	Facility Lease Payments		Remainder of 2020		2021		2022		2023		2024		Thereafter		Facility Lease Payments		Remainder of 2021		2022		2023		2024		2025		Thereafter

Remaining Facility Lease Payments	$	1,429,000	$	85,000	$	345,000	$	355,000	$	364,000	$	280,000	$	—	$	1,173,000	$	174,000	$	355,000	$	364,000	$	280,000	$	—	$	—
Less: Discount Adjustment		(152,000)														(102,000)
Total lease liability	$	1,277,000													$	1,071,000

Lease liability-current portion	$	278,000													$	298,000

Long-term lease liability	$	999,000													$	773,000

The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of ~~September~~June 30, ~~2020:~~2021:


	ROU Asset		ROU Asset

Balance as of December 31, 2019	$	1,003,000
Balance as of December 31, 2020			$	824,000
Amortization		(133,000)		(96,000)
Balance as of September 30, 2020	$	870,000
Balance as of June 30, 2021			$	728,000

The Company recorded lease expense in the respective periods is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020

Lease expense	$	66,000	$	65,000	$	198,000	$	196,000	$	67,000	$	66,000	$	140,000	$	132,000

Note 8 – Warrants

The Company has issued ~~equity-classified warrants~~both equity (“placement agent”) and liability (“investor”) classified warrants in conjunction with previous equity raises. The Company had a total of ~~2.2~~1.6 million equity-classified warrants and ~~3.2~~2.2 million ~~liability~~liability-classified warrants outstanding as of ~~September~~June 30, ~~2020.~~2021.

The following table summarizes the Company’s warrant activity during the six months ended June 30, 2021:


		Weighted		Weighted Average
	Number of	Average		Remaining
	Warrants	Exercise Price		Contractual Life

Outstanding as of December 31, 2020	4,130,724	$	0.66	2.05
Warrants exercised	(357,126)	$	0.42	—
Outstanding as of June 30, 2021	3,773,598	$	0.68	1.49

1715

Table of Contents

The following table summarizes the Company’s outstanding warrants between placement agent and investor warrant ~~activity during the nine months ended September 30, 2020:~~classifications:

Weighted

Weighted Average

Number of

Average

Remaining

Warrants

Exercise Price

Contractual Life

Outstanding as of December 31, 2019

7,116,000

$
0.57

3.41
Warrants issued

—

$
—

Warrants exercised

(1,668,000)

$
0.42

Warrants expired

—

$
—

Outstanding as of September 30, 2020

5,448,000

$
0.61

2.52


		Weighted		Weighted Average
	Number of	Average		Remaining
	Warrants	Exercise Price		Contractual Life

Investor warrants at $0.76	2,026,915			0.92
Placement agent warrants at $0.76	422,233			0.92
Placement agent warrants at $0.94	150,000			0.16
Investor warrants at $0.40	153,400			2.12
Placement agent warrants at $0.50	1,021,050			2.97
Outstanding as of June 30, 2021	3,773,598	$	0.68	1.49

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company issued ~~1.2 million~~284,100 shares of its common stock as a result of the exercise of investor warrants with an exercise price of $0.40. The Company received proceeds of ~~$465,000~~$114,000 during the ~~nine months ended September 30, 2020~~period related to these investor warrant exercises. In addition, former placement agents elected to exercise ~~506,000~~73,026 of their warrants utilizing the net exercise option, where the total number of shares of common stock issued was reduced to cover the exercise price and, as such, the Company issued ~~276,000~~51,763 shares of common ~~stock as a result.~~stock. The Company did not receive any cash related to the exercise of placement agent warrants.

The total value for the warrant derivative liability as of ~~September~~June 30, ~~2020~~2021 is approximately ~~$1.9 million. See~~$2.3 million (see Note 9~~for additional information regarding the warrant derivative liability.~~).

Note 9 - Fair Value Considerations

Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs ~~are~~reflect inputs that market participants would use in pricing the asset or liability based on market data obtained from sources not affiliated with the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:


	Level 1:	Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities;

	Level 2:	Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and

	Level 3:	Unobservable inputs that are supported by little or no market activity.

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. Warrants are recorded at estimated fair value utilizing the Black-Scholes warrant pricing model.

The Company’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques in all periods presented.

1816

Table of Contents

The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, by level within the fair value hierarchy:


	Fair Value Measurements Using								Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
September 30, 2020
June 30, 2021
Liabilities:
Warrant derivative liability	$	0	$	0	$	1,901,000	$	1,901,000	$	0	$	0	$	2,340,000	$	2,340,000

December 31, 2019
December 31, 2020
Liabilities:
Warrant derivative liability	$	0	$	0	$	2,064,000	$	2,064,000	$	0	$	0	$	2,607,000	$	2,607,000

The warrant derivative liability for both periods presented was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments.

The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy:


	Derivative Instruments		Derivative Instruments

Balance as of December 31, 2019	$	2,064,000
Balance as of December 31, 2020			$	2,607,000
Warrant exercises		(912,000)		(347,000)
Change in fair value		749,000		80,000
Balance as of September 30, 2020	$	1,901,000
Balance as of June 30, 2021			$	2,340,000

Note 10 - Common Stock

Authorized Shares

The Company had 300.0 million authorized shares of common stock as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

The following table summarizes the Company’s remaining authorized shares available for future issuance:


	~~September~~June 30, ~~2020~~2021

Authorized shares		300,000,000

Common stock outstanding		~~183,938,000~~200,070,419
Options outstanding		~~5,484,000~~5,686,989
Warrants outstanding		~~5,448,000~~3,773,598
Reserved for issuance under 2019 Stock and Incentive Plan		~~8,643,000~~7,918,755

Available shares		~~96,487,000~~82,550,239

~~Table of Contents~~

~~Shelf Registration~~

In March 2017, the Company filed a shelf registration statement on Form S-3 (the “Prior Shelf Registration Statement”) with the SEC to register the offering by the Company, from time to time, of up to $100.0 million of the Company’s common stock, preferred stock, debt securities, warrants and units, as well as, the sale by selling stockholders of 5.0 million shares of common stock. The Prior Shelf Registration Statement was declared effective by the SEC in April 2017 and was terminated in May 2020. In April 2020, the Company filed a shelf registration statement on Form S-3 (the “New Shelf Registration Statement”) with the SEC to register the offering by the Company, from time to time, of up to $100.0 million of the Company’s common stock, preferred stock, debt securities, warrants and units, which was declared effective by the SEC in May 2020. The Company had $88.4 million remaining under the New Shelf Registration Statement as of September 30, 2020. However, the Company’s ability to issue and sell securities under the New Shelf Registration Statement may be limited, based on many factors including, but not limited to, the Company’s stock price and related volatility, the trading volume of the Company’s common stock, and the number of remaining authorized shares available for the Company to issue.

ATM Equity Offering Program

~~Sales Agreement~~

In February 2020, the Company entered into a Sales Agreement with 2 agents to implement an ATM equity offering program under which the Company, from time to time and at its sole discretion, may offer and sell shares of its common stock having an aggregate offering price up to $50.0 million to the public through the agents until (i) each agent declines to accept the terms for any reason, (ii) the entire amount of shares has been sold, or (iii) the Company suspends or terminates the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the agents shall use their

Table of Contents

commercially reasonable efforts to sell shares from time to time, based upon the Company’s instructions as documented on a purchase notification form. If an agent declines to accept the purchase notification form, the agent must promptly notify the Company and the other agent then has the ability to accept or decline the purchase notification form. The Company has no obligation to sell any shares and may, at any time and in its sole discretion, suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Sales Agreement includes customary indemnification rights in favor of the agents and provides that the agents will be entitled to an aggregate fixed commission of 4.0% of the gross proceeds (2.0% to each agent) to the Company from any shares sold pursuant to the Sales Agreement.

The following table summarizes the Company’s sales and related issuance costs incurred under the Sales Agreement ~~as of September~~during the three months ended March 31, 2021 and June 30, ~~2020:~~2021:


	Three months ended		Three months ended		Three months ended
	March 31, 2020		June 30, 2020		September 30, 2020		Total		Three months ended March 31, 2021		Three months ended June 30, 2021		Total

Total shares of common stock sold		1,241,000		13,069,000		9,405,000		23,715,000		1,848,437		4,066,773		5,915,210

Average price per share	$	0.58	$	0.54	$	0.78	$	0.64

Gross Proceeds	$	682,000	$	7,231,000	$	7,223,000	$	15,136,000
Gross proceeds									$	2,705,000	$	7,267,000	$	9,972,000
Commissions earned by placement agents		(27,000)		(290,000)		(290,000)		(607,000)		(109,000)		(291,000)		(400,000)
Issuance / subsequent recurring fees		(219,000)		(24,000)		(23,000)		(266,000)
Net Proceeds	$	436,000	$	6,917,000	$	6,910,000	$	14,263,000
Issuance fees										(17,000)		(30,000)		(47,000)
Net proceeds									$	2,579,000	$	6,946,000	$	9,525,000

~~Table of Contents~~

Common Stock Issued for Services

The Company issued ~~136,000~~54,052 and ~~136,000~~136,236 shares of common stock under the Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan (the “2019 Plan”), each valued at $80,000, ~~and $60,000,~~ as partial compensation for the services of non-employee directors, during the ~~nine~~six months ended ~~September~~June 30, 2021 and 2020, ~~and 2019,~~ respectively.

Note 11 - Equity

Options

In December 2019, the Company’s Board of Directors and stockholders approved the adoption of the ~~Ampio Pharmaceuticals, Inc.~~ 2019 ~~Stock and Incentive~~ Plan, ~~(the “2019 Plan”),~~ under which shares were reserved for future issuance of equity related awards classified as option awards/grants, restricted stock awards and other equity related awards. The 2019 Plan permits grants of equity awards to employees, directors and consultants. The stockholders approved a total of 10.0 million shares to be reserved for issuance under the 2019 Plan. The Company’s previous 2010 Stock and Incentive Plan (the “2010 Plan”) was cancelled concurrently with the adoption of the 2019 Plan.

The following table summarizes the activity of the 2019 Plan and the shares available for future equity awards as of ~~September~~June 30, ~~2020:~~2021:


	2019 Plan

Total shares reserved for equity awards		10,000,000
Options granted during previous fiscal ~~2019~~years		~~(144,000)~~(2,067,471)
Options granted during fiscal ~~2020~~2021		~~(1,218,000)~~(36,000)
~~Add back:~~Forfeited, expired ~~forfeited~~ and/or cancelled equity awards		~~5,000~~22,226
Remaining shares available for future equity awards		~~8,643,000~~7,918,755

~~The following table summarizes the Company’s stock option activity under both the 2010 Plan and 2019 Plan during the nine months ended September 30, 2020:~~

Weighted

Weighted Average


Number of

Average

Remaining

Aggregate

Options

Exercise Price

Contractual Life

Intrinsic Value
Outstanding as of December 31, 2019

6,000,000

$
1.33

5.40

$
—
Granted

1,218,000

$
0.67

Exercised

(20,000)

$
0.54

Forfeited

(100,000)

$
1.70

Expired and/or cancelled

(1,614,000)

$
0.87

Outstanding as of September 30, 2020

5,484,000

$
1.11

7.26

$
1,435,000
Exercisable as of September 30, 2020

5,335,000

$
1.12

7.21

$
1,388,000

Of the 1.2 million stock options that were granted during the nine months ended September 30, 2020, 604,000 stock options were reissued as replacements for 711,000 stock options that were cancelled. The value of the reissued stock options was estimated using the Black-Scholes option pricing model and totaled $277,000. The 100,000 stock options that were forfeited and approximately ~~1.6~~ million stock options that expired and/or were cancelled during the nine months ended September 30, 2020 were issued under the 2010 Plan, which was cancelled as noted above. Therefore, these forfeited and expired and/or cancelled stock options were not added back to the 2019 Plan. The 20,000 stock options that were exercised were processed as a net exercise, where the total number of shares of common stock issued was reduced to cover the option holders’ exercise price and tax obligations. The Company submitted the tax obligations on behalf of the option holders and did not receive any cash proceeds from the net exercise.

2118

Table of Contents

The following table summarizes the Company’s stock option activity during the six months ended June 30, 2021:


		Weighted		Weighted Average
	Number of	Average		Remaining		Aggregate
	Options	Exercise Price		Contractual Life		Intrinsic Value
Outstanding as of December 31, 2020	6,099,651	$	1.04	7.36	$	—
Granted	36,000	$	1.76
Exercised	(443,662)	$	0.55
Forfeited, expired and/or cancelled	(5,000)	$	1.75
Outstanding as of June 30, 2021	5,686,989	$	1.08	6.92	$	4,661,000
Exercisable as of June 30, 2021	5,413,989	$	1.09	6.80	$	4,471,000

Of the 443,662 stock options that were exercised during the six months ended June 30, 2021, 8,000 stock options were cash exercised whereby the Company received proceeds to cover the option holder’s exercise price and tax obligations totaling $6,000. In addition, 302,734 stock options were exercised as cashless exercises whereby the Company received proceeds to cover the option holders’ exercise price totaling $154,000. The remaining 132,928 stock options were net exercised whereby the total number of shares of common stock issued was reduced to cover the option holders’ exercise price and tax obligations. The Company submitted the tax obligations totaling $40,000 on behalf of the option holders. The shares of common stock that are held back upon a net exercise of a stock option to settle the option holder’s obligation associated with the exercise price and tax obligations are added back to the reserve for shares available for future equity awards under the 2019 Plan.

The following table summarizes the outstanding options that were issued in accordance with the 2010 Plan and the 2019 Plan:


Outstanding Options by Plan	June 30, 2021
2010 Plan		3,640,018
2019 Plan		2,046,971
Outstanding as of June 30, 2021		5,686,989

Stock options outstanding as of ~~September~~June 30, ~~2020~~2021 are summarized in the table below:


	Number of	Weighted		Weighted Average	Number of	Weighted		Weighted Average
	Options	Average		Remaining	Options	Average		Remaining
Range of Exercise Prices	Outstanding	Exercise Price		Contractual Lives	Outstanding	Exercise Price		Contractual Lives
Up to $0.50	704,000	$	0.44	8.77	494,500	$	0.44	8.17
$0.51 - $1.00	4,092,000	$	0.61	7.01	4,152,345	$	0.71	7.14
$1.01 - $1.50	50,000	$	1.03	9.85	187,000	$	1.39	9.38
$1.51 and above	638,000	$	4.48	2.87	853,144	$	3.23	4.59
	5,484,000	$	1.11	7.26
Total					5,686,989	$	1.08	6.92

The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company computed the fair value of options granted/modified during the period ended ~~September~~June 30, ~~2020,~~2021, using the following assumptions:

Table of Contents


Expected volatility	~~120.80% - 201.90~~127.17	%
Risk free interest rate	~~0.19% - 1.67~~0.78	%
Expected term (years)	~~3.00 - 5.51~~5.00

Stock-based compensation expense related to the fair value of stock options is included in the statements of operations as research and development expenses or general and administrative expenses as set forth in the table below. The following table summarizes stock-based compensation expense (stock options and common stock issued for services) for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019:~~2020:

Three Months Ended September 30,

Nine Months Ended September 30,


2020

2019

2020

2019
Research and development expenses








Stock-based compensation

$
72,000

$
46,000

$
142,000

$
77,000

General and administrative expenses






Issuance of common stock for services

0

0

80,000

60,000
Stock-based compensation

405,000

209,000

612,000

278,000

Total stock-based compensation

$
477,000

$
255,000

$
834,000

$
415,000

Unrecognized expense as of September 30, 2020

$
28,000





Weighted average remaining years to vest

0.24


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Research and development expenses
Stock-based compensation	$	—	$	11,000	$	46,000	$	71,000

General and administrative expenses
Issuance of common stock for services		0		0		80,000		80,000
Stock-based compensation		67,000		53,000		187,000		206,000

Total stock-based compensation	$	67,000	$	64,000	$	313,000	$	357,000

Unrecognized expense as of June 30, 2021	$	98,000

Weighted average remaining years to vest		1.12

Note 12 - Earnings Per Share

Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is based on the treasury stock method and computed by dividing net loss available to common stockholders by the diluted weighted-average shares of common stock outstanding during each period. The Company’s potentially dilutive shares include stock

~~Table of Contents~~

options and warrants for the shares of common stock. The potentially dilutive shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when the effect is dilutive. The investor warrants are treated as equity in the calculation of diluted earnings per share in both the computation of the numerator and denominator, if dilutive. The following table sets forth the calculations of basic and diluted earnings per share for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019:~~2020:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Net (loss) income	$	(3,368,000)	$	(7,219,000)	$	(11,277,000)	$	(12,610,000)
Net loss									$	(3,556,000)	$	(2,731,000)	$	(7,222,000)	$	(7,910,000)
Less: decrease in fair value of investor warrants		—		—		(163,000)		—		(116,000)		—		(267,000)		(156,000)
Loss available to common stockholders	$	(3,368,000)	$	(7,219,000)	$	(11,440,000)	$	(12,610,000)	$	(3,672,000)	$	(2,731,000)	$	(7,489,000)	$	(8,066,000)

Basic weighted-average common shares outstanding		178,622,000		142,208,000		168,062,000		122,895,000		196,179,371		166,392,893		195,785,398		162,723,309
Add: dilutive effect of equity instruments		—		—		1,292,000		—		5,268,667		—		5,199,951		1,182,948
Diluted weighted-average shares outstanding		178,622,000		142,208,000		169,354,000		122,895,000		201,448,038		166,392,893		200,985,349		163,906,257
Earnings per share – basic	$	(0.02)	$	(0.05)	$	(0.07)	$	(0.10)	$	(0.02)	$	(0.02)	$	(0.04)	$	(0.05)
Earnings per share – diluted	$	(0.02)	$	(0.05)	$	(0.07)	$	(0.10)	$	(0.02)	$	(0.02)	$	(0.04)	$	(0.05)

Table of Contents

The potentially dilutive shares of common stock that have been excluded from the calculation of net loss per share because of ~~the~~their anti-dilutive effect are as follows:


	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended June 30,		Six Months Ended June 30,
	2020	2019	2020	2019	2021	2020	2021	2020
Outstanding stock options	5,484,000	5,914,000	4,567,000	5,914,000	1,437,657	6,866,524	1,466,319	5,917,367
Warrants to purchase shares of common stock	5,448,000	23,508,000	5,073,000	23,508,000	2,754,263	5,374,832	2,794,317	5,141,041
Total potentially dilutive shares of common stock	10,932,000	29,422,000	9,640,000	29,422,000	4,191,920	12,241,356	4,260,636	11,058,408

Note 13 – Litigation

~~On August 25, 2018, a purported stockholder of~~From time to time, the Company ~~commenced~~may be a ~~putative class action lawsuit~~party to litigation arising in the ~~United States District Court for the Central District~~ordinary course of California (the “Court”), captioned Shi v. Ampio Pharmaceuticals, Inc., et al., Case No. 18-cv-07476 (the “Securities Class Action”). The plaintiff in the Securities Class Action alleged that the Company and certain of its current and former officers had violated the federal securities laws by misrepresenting and/or omitting material information regarding the AP-003 Phase III clinical trial of Ampion. The plaintiff asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Securities and Exchange Commission Rule 10b-5, on behalf of a putative class of purchasers of the Company’s common stock from December 14, 2017 through August 7, 2018. The plaintiff in the Securities Class Action sought unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On September 27, 2019, the Court presiding over the Securities Class Action issued an order appointing a Lead Plaintiff and Lead Counsel, pursuant to the Private Securities Litigation Reform Act. The Lead Plaintiff filed an amended complaint in late 2019. The Company filed a motion to dismiss the amended complaint on February 10, 2020. On March 26, 2020, the Lead Plaintiff filed a brief in opposition to the Company’s motion to dismiss. The Company filed a reply to the Lead Plaintiff’s brief in opposition on April 27, 2020. On June 19, 2020, the Court granted the Company’s motion to dismiss and dismissed the Securities Class Action with prejudice. The plaintiff did not file a notice of appeal, and the case is now concluded.

On September 10, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the Central District of California, captioned Cetrone v. Macaluso, et al., Case No. 18-cv-07855 (the “Cetrone Action”), alleging primarily that the directors and officers of Ampio had breached their fiduciary duties in connection with alleged misstatements and omissions regarding the AP-003 Phase III clinical trial of Ampion. The

~~Table of Contents~~

~~plaintiff sought unspecified damages, certain governance reforms, pre-judgment and post-judgment interest, attorneys’ fees and costs.~~

On October 5, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the District of Colorado, Theise v. Macaluso, et al., Case No. 18-cv-02558 (the “Theise Action”), which closely paralleled the allegations in the Cetrone Action. A second derivative action was filed in the United States District Court for the District of Colorado and was consolidated with the Theise Action under the caption In re: Ampio Pharmaceuticals Inc. Stockholder Derivative Actions, Case No. 18-cv-02558. The plaintiffs sought unspecified damages, pre-judgment and post-judgment interest, attorneys’ fees and costs. On August 28, 2020, the District Court for the Central District of California dismissed the Cetrone Action in its entirety and without prejudice, pursuant to a Stipulation of Dismissal between the parties. On August 31, 2020, the United States District Court for the District of Colorado similarly dismissed the Theise Action in its entirety and without prejudice, pursuant to a Stipulation of Dismissal between the parties.

business. As of ~~September~~June 30, ~~2020, each of the Securities Class Action, the Cetrone Action and the Theise Action have been dismissed. As of the date hereof,~~2021, the Company is not a party to any ongoing lawsuits.

Note 14 – Subsequent Events

In July 2021, the Company received additional gross proceeds of $0.5 million from the sale of 330,875 shares of common stock in an ATM offering pursuant to the Sales Agreement, which was offset by offering related costs of $22,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion should be read in conjunction with our historical financial statements. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see “Cautionary Note Regarding Forward-Looking Statements”, above, Part II, Item 1A of this Quarterly Report on Form 10-Q, “Risk Factors,” and the risk factors included in our ~~2019~~2020 Annual ~~Report.~~Report and other reports that we have filed with the SEC.

EXECUTIVE SUMMARY

We are a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. We have not generated operating revenue to date, and our operations have been substantially funded through equity raises, which have occurred from time to time since inception.

The ~~pharmaceutical~~biopharmaceutical market, both domestic and globally, is a highly competitive industry with strict regulations that are unpredictable in nature, time intensive and costly. We are committed to offering a compelling therapeutic option for patients most in need of new treatments for inflammatory conditions, ~~such as Osteoarthritis of the Knee (“OAK”),~~including, but not limited to, OAK and ~~for~~ the treatment of serious complications arising from the COVID-19 pandemic, including ~~the need for supplemental oxygen and the rapid onset of respiratory failure, termed Acute Respiratory Distress Syndrome (“ARDS”) or Acute Lung Injury (“ALI”)~~Long-COVID.

Moving forward, we will continue to place a disciplined focus on maintaining our business operations in a manner that is streamlined and efficient while continuing to allocate a requisite level of our liquidity, human capital and other operational resources towards the advancement of key immunology-based therapies with the ultimate goal of achieving FDA marketing approval and subsequent commercialization of Ampion for these conditions.

Table of Contents

Overview

We maintain an Internet website at www.ampiopharma.com. Information on or linked to our website is not incorporated by reference into this Quarterly Report on Form 10-Q. Filings with the SEC can also be obtained at the SEC’s website, www.sec.gov.

~~Table of Contents~~

Ampion, our lead product candidate, is in the process of advancing through clinical trials in the United States. Ampion is currently in development as an intra-articular injection treatment for severe ~~OAK;~~OAK, an IV treatment for COVID-19 patients, ~~who require supplemental oxygen;~~ and an inhaled treatment for COVID-19 ~~induced respiratory distress~~and Long-COVID. Pre-clinical and discovery work is also underway for additional applications and indications for Ampion.

In June 2019, we commenced ~~our~~the AP-013 study titled “A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with Pain Due to Severe Osteoarthritis of the Knee”. In January 2020, the United States Department of Health and Human Services declared COVID-19 a public health emergency in the United States and in March 2020, the WHO declared the COVID-19 outbreak a global pandemic. In April 2020, due to the impact of COVID-19, we paused the ongoing conduct of the AP-013 study. ~~As increases in COVID-19 cases across~~During fiscal 2020 and fiscal 2021, the ~~United States continue to be reported, we have determined that the AP-013 study will remain paused, but we continue to actively explore viable options to enable us to complete the study. Recently, the~~ FDA ~~has~~ provided guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were ~~adversely~~ impacted by the pandemic. ~~We are currently reviewing~~In March 2021, we submitted a detailed proposal to the FDA ~~guidance as it relates~~in response to the ~~AP-013 study data with~~FDA’s recent guidance regarding the ~~expectation that we will finalize a proposal on how we plan to approach~~status of the AP-013 ~~study during~~study. In May 2021, the ~~fourth quarter~~FDA issued updated statistical guidance for the industry. At this time, we are evaluating our options to analyze the clinical trial data from the AP-013 study. However, due to the significant uncertainty surrounding the continuation and overall impact of ~~fiscal 2020. However,~~the pandemic, it is possible that the continuation of the ~~COVID-19~~ pandemic may prevent completion of the AP-013 study at this time or at all. ~~Finally, due to~~In addition, the current uncertainty resulting from the ~~COVID-19~~ pandemic may result in a significant change to the future contractual commitment ~~amount~~ related to the AP-013 ~~study may significantly increase.~~study.

In ~~June~~October 2020, ~~we received FDA agreement to proceed with human trials utilizing an IV Ampion treatment for COVID-19 patients who require supplemental oxygen, and~~ we commenced a ~~Phase I~~ study ~~for such treatment, known as~~(the “AP-014 study”) titled “A Randomized Controlled Trial to Evaluate the ~~AP-016 study,~~Safety and Efficacy of Nebulized Ampion In Adults with Respiratory Distress Secondary to COVID-19 Infection”. In March 2021, we finalized the enrollment of 40 patients, who were randomized 1:1, Ampion in July 2020. In September 2020, we completed the AP-016 study, and the results of the study found Ampion to be safe and well-tolerated. The patients in the study will be followed for a period of 90-days subsequentaddition to the ~~completion~~Standard of ~~the~~Care (“SOC”) versus SOC alone. Patients were randomized to receive inhaled Ampion for five days. The study ~~in order to complete their safety assessments. Secondary efficacy endpoints from the study suggest that Ampion may improve the clinical outcome for patients with COVID-19. We believe that~~met its primary end-point and demonstrated the safety and ~~efficacy results could provide~~tolerability of inhaled Ampion in COVID-19 patients. Additionally, a reduction in mortality was observed by nearly 80% of patients with Ampion treatment compared to SOC alone. It was also noted that Ampion treated patients required less hospital time and were stable or showed improvement on a scale of clinical improvement compared to patients treated with SOC alone. This data was presented to the ~~basis~~FDA for ~~performing further clinical trials with IV Ampion.~~guidance as a potential Emergency Use Authorization (“EUA”) therapy. The FDA provided guidance and recommended the Company proceed to a Phase II study in COVID-19 patients.

In ~~September~~December 2020, we ~~received FDA agreement to proceed~~initiated the multicentered AP-017 study in the United States and Israel for IV Ampion therapy in patients with ~~human trials utilizing Ampion by inhalation as a treatment for COVID-19 patients who have respiratory distress, and we expect to commence a Phase I study for such treatment, known as~~COVID-19. The preliminary results of the AP-014 study ~~during~~were shared with the ~~fourth quarter~~FDA, at which point the FDA recommended updates to the protocol for the AP-017 study, which were implemented in the study titled “A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of ~~fiscal 2020.~~Intravenous Ampion in Adult COVID-19 Patients Requiring Oxygen Supplementation”. In June 2021, due to the ongoing turmoil in the region, we decided to pause the AP-017 study in Israel. However, we plan to continue conducting the AP-017 study in the United States.

In March 2021, we initiated the AP-018 study titled “A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients with Prolonged Respiratory Symptoms due to COVID-19 (Long-COVID)”. An increasing number of people with COVID-19 are experiencing lingering effects of COVID-19 and continue to have prolonged respiratory complications months after the onset of the disease, also known as PASC, Long-COVID, and/or long-hauler syndrome. This study aims to evaluate the safety of Ampion and the clinical outcomes in patients with Long-COVID.

In April 2021, we initiated the multicentered AP-019 study titled “A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults with Respiratory Distress Due to COVID-19”, following the strong top-line results achieved from the AP-014 study. In June 2021, we announced randomization and dosing of patients in the AP-019 study in the United States. In June 2021, we also received approval to expand enrollment of the AP-019 study to India.

Table of Contents

In April 2021, we provided an update on the continued research and discovery for Ampion applications. Laboratory results suggest Ampion’s suitability for addressing kidney diseases and provides further evidence that it is a platform biologic for treatment of a wide variety of inflammatory and autoimmune diseases.

We believe the immunomodulatory action and anti-inflammatory effects of Ampion may provide a treatment for individuals with inflammatory conditions including, but not limited to, severe OAK and the widespread inflammation associated with COVID-19 infection.

Our therapeutic product pipeline is the result of more than two decades of research at leading hospital-based research centers. Significant discoveries in both scientific and clinical research have been published in peer-reviewed journals, highlighting the depth of research supporting Ampion’s therapeutic capabilities. Ampion is backed by an extensive and robust United States and global patent portfolio with intellectual property protection extending through 2037. In addition, Ampion is eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act of 2009.

AMPION

We have developed a novel biologic drug, Ampion, which contains a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease. In vitro studies have shown that Ampion represses the transcription of proteins responsible for inflammation, while activating anti-inflammatory proteins responsible for signaling tissue growth and healing. Ampion achieves its biological effect by targeting the over production of inflammatory cytokines, which is common in multiple inflammatory diseases like osteoarthritis and respiratory disease, and other inflammatory conditions. Ampion has been shown to uniquely reduce inflammation along multiple pathways, unlike other anti-inflammatory therapies that target only one mechanism.

Ampion has been developed for use, and has been cleared by the FDA for investigation, by multiple routes of administration.

●

Intra-articular injection places Ampion right where it is needed to locally treat inflammation. The osteoarthritis trials are evaluating the safety and efficacy of intra-articular injection into the joint.

●

Inhalation provides direct application of Ampion to locally treat inflammation in the lungs. Certain COVID-19 clinical trials are evaluating the safety and efficacy of Ampion inhalation in the lungs of COVID-19 patients with respiratory illness, which is supported by strong top-line results achieved from the AP-014 study.

●

Intravenous provides systemic application of Ampion to broadly treat inflammation throughout the body. An additional COVID-19 clinical trial is evaluating the safety and efficacy of Ampion IV treatment in COVID-19 patients with respiratory illness.

Table of Contents

We believe that ~~this~~the Ampion mechanism of action provides a therapeutic effect by interrupting the dysregulated immune system responsible for the disease, damage, and pain attributed to many inflammatory and degenerative conditions.

~~Table of Contents~~ Ampion is considered a platform drug which is potentially useful for several inflammatory diseases throughout the body.

Ampion for Osteoarthritis

Ampion targets the cellular pathways in the innate immune response correlated with pain, inflammation, and joint damage infrom osteoarthritis. As described above, in vitro studies have shown that Ampion represses the transcription of inflammatory cytokines responsible for inflammation, while activating anti-inflammatory proteins responsible for tissue growth and healing. We believe that this mechanism of action interrupts the disease process responsible for the pain and disability associated with OAK while providing a market expansion potential as a disease modifying biologic drug.

We are currently developing Ampion as an intra-articular injection to treat the signs and symptoms of severe OAK, which continues to be a growing epidemic in the United States and other countries worldwide. OAK is a progressive disease characterized by gradual degradation and loss of cartilage due to inflammation of the soft tissue and bony structures of the knee joint. Progression of the most severe form of OAK leaves patients with little or no treatment options other than a total knee arthroplasty. The FDA has asserted that severe OAK is an “unmet medical need” with no existing licensed therapy available. While we believe that Ampion could successfully treat this “unmet medical need”, our ability to market this product is subject to FDA approval.

Ampion Development for Osteoarthritis

Since our inception, we have conducted multiple clinical trials and have advanced through late-stage clinical trials in the United States, initially under the guidance of the FDA’s Office of Blood Research and Review and most recently under the guidance of the FDA’s Office of Tissues and Advanced Therapies.

Study AP-003-A was a multicenter, randomized, double-blind Phase III trial of 329 patients who were randomized 1:1 to receive Ampion or saline control via intra-articular injection. The study showed a statistically significant reduction in pain compared to the control, with an average of greater than 40% reduction in pain from baseline at 12 weeks with Ampion treatment. Patients who received Ampion also showed a significant improvement in function and quality of life at 12 weeks compared to patients who received the saline control at 12 weeks. Quality of life was assessed using Patient Global Assessment. Furthermore, the trial included severely diseased patients, defined radiographically as Kellgren Lawrence Grade 4 (“KL 4”). From this patient population, those patients who received Ampion had a significantly greater reduction in pain than those who received the saline control. Ampion was well tolerated with minimal adverse events reported in either the Ampion or saline treated groups. There were no drug-related serious adverse events in either group.

Table of Contents

In 2018, the FDA reiterated and confirmed that our successful pivotal Phase III clinical trial, AP-003-A, was adequate and well-controlled, provided evidence of the effectiveness of Ampion and can contribute to the substantial evidence of effectiveness necessary for the approval of a ~~Biologics License Application (“BLA”).~~BLA. The FDA provided guidance that we should complete an additional Phase III trial of KL 4 severe OAK patients with concurrent controls that would be

~~Table of Contents~~

carried out under ~~a Special Protocol Assessment (“SPA”)~~an SPA to obtain FDA concurrence on the trial design prior to initiation of the trial.

We received an SPA agreement in June 2019 from the FDA for a Phase III clinical protocol in reference to the AP-013 study. The SPA agreement for the AP-013 study finalized patient enrollment at 1,034 patients, with a sample size assessment at an interim analysis of 724 patients to allow an adjustment up to 1,551 patients if deemed necessary. In the SPA agreement, the FDA agreed that the design and planned analysis of the AP-013 study adequately addressed the objectives necessary to support a regulatory submission. According to the FDA’s guidance regarding SPAs (published in April 2018), an SPA documents the FDA’s agreement that the design and planned analysis of a study can address objectives in support of a regulatory submission; however, the final determinations for marketing application approval are made after a complete review of the marketing application and are based on the entire data in the application. Following the receipt of the SPA agreement, we initiated the AP-013 study, identified and engaged clinical sites for the clinical trial, and initiated dosing of patients at those sites. ~~As of December 31, 2019, we completed the enrollment and dosing of 724 patients required for the interim analysis sample size assessment.~~

~~As previously noted, in March~~In January 2020, the ~~WHO~~Secretary of HHS declared COVID-19 a public health emergency in the ~~COVID-19 outbreak a pandemic~~United States and the WHO announced a global health emergency because of COVID-19. The CDC indicated that older adults, age 65 years and older, are at higher risk for severe illness as a result of COVID-19. The AP-013 study focuses on individuals with the most severely diseased OAK, which represents an underserved patient population typically excluded from clinical studies because of the intractable nature of their condition. The AP-013 study population is comprised of elderly patients with an average age of 65 years old and a maximum age of 87 years. Therefore, guidance from the CDC indicates the AP-013 study population is the highest risk demographic for developing severe illness during the current COVID-19 pandemic. In March 2020, and most recently updated on January 27, 2021, the FDA acknowledged the impact of COVID-19 on clinical trials in a published guidance, “FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 Pandemic”, which outlines the ~~Agency’s~~FDA’s recommendations for ensuring clinical trial participant safety and adherence to good clinical practice guidelines and protocol requirements for clinical trials during the outbreak. In concurrence with the FDA guidance, the ~~Safety Monitoring Committee (“SMC”)~~SMC for the AP-013 study recognized the impact of COVID-19 on the clinical trial. In April 2020, we paused ongoing conduct of the AP-013 ~~study, and~~study. In March 2021, we ~~continue~~submitted a detailed proposal to ~~monitor~~ the ~~COVID-19 health situation and~~FDA in response to the FDA’s guidance regarding the status of the AP-013 study. In April 2021, we received a response to our proposal from the FDA. In May 2021, the FDA issued updated ~~FDA~~statistical guidance ~~on conducting~~for the industry. At this time, we are evaluating our options to analyze the clinical ~~trials in a pandemic. Increases in COVID-19 cases across~~trial data from the ~~United States continue to be reported, therefore, we have determined that~~AP-013 study. During this period, the AP-013 study will remain paused ~~as we continue~~and blinded to ~~explore options to enable us to complete the study. Currently, the Company is evaluating options for the AP-013 study using the FDA guidance,~~ ~~“Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency”~~~~, which is specifically designed to assist the pharmaceutical industry with viable options for evaluating data from~~ensure clinical ~~trials which were adversely impacted by the pandemic. In order to remain in~~trial integrity and compliance with ~~such guidance, we plan to submit a proposal~~the SPA. However, due to the ~~FDA during~~significant uncertainty surrounding the ~~fourth quarter of fiscal 2020 to maintain~~continuation and overall impact from the ~~SPA for the AP-013 study. However,~~pandemic, it is possible that the ~~COVID-19~~continuation of the pandemic may prevent completion of the AP-013 study at this time or at all. In addition, the current uncertainty resulting from the pandemic may result in a significant change to the future contractual commitment related to the AP-013 study.

Ampion for ~~Complications Related to~~ COVID-19 ~~Infection~~

The COVID-19 pandemic has resulted in millions of cases and ~~hundreds of thousands of~~ deaths worldwide with figures continuing to reflect significant expansion of the pandemic. The COVID-19 infection is an acute respiratory illness caused by a novel coronavirus (SARS-COV-2). Once infected, the COVID-19 virus moves into a patient’s respiratory tract where the lungs may become inflamed, making breathing difficult and requiring treatment with oxygen. ~~The CDC has estimated that approximately 20% of patients with COVID-19 will progress to a severe disease condition, requiring hospitalization and clinical care.~~ Complications of severe COVID-19 infection include, ~~ARDS,~~but are not limited to, Acute Respiratory Distress Syndrome (“ARDS”), Acute Lung Injury (“ALI”), PASC, pneumonia, sepsis and septic shock, cardiomyopathy and arrhythmia, acute kidney injury and prolonged hospitalization for other complications ~~(e.g.~~(i.e., secondary bacterial infection). ~~The primary cause of death associated with COVID-19 infection is ARDS, and, as of the date of this filing, there are no clinically approved treatments for ARDS or the COVID-19 infection.~~

~~An article published in the peer-reviewed journal,~~ ~~The Journal of the American Medical Association~~~~, by Bellani et al. in February 2016 titled, ‘~~~~Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries~~’, indicates that under normal circumstances, there is approximately a 40% mortality rate for patients with ARDS. COVID-19 is newly emerging, and there is little published research on mortality in this subset of patients; however, we believe that ARDS secondary to COVID-19 infection may prove to be

~~Table of Contents~~

more lethal than ARDS due to other causes. A study of 191 patients in Wuhan, China reported that 50 of the 54 patients with COVID-19 who died during their hospitalization developed ARDS, while only nine of the 137 survivors developed ARDS. That study, published in ~~The Lancet~~ by Zhou et al. in March 2020, demonstrates an 85% (50/59) case mortality rate for ARDS secondary to COVID-19 infection, which is more than double the mortality rate observed without COVID-19 infection.

~~The CDC has reported that, among all patients with a COVID-19 infection, between 3% - 17% develop ARDS, but that percentage increases to 67% - 85% for patients admitted to an intensive care unit.~~ We believe that it is imperative that effective therapeutic treatments are identified and developed to address the full spectrum of clinical features of COVID-19 infection, from the need for oxygen to the progression to ARDS. ~~For instance, it has been reported that treatments that reduce~~

Nonclinical in vitro studies show Ampion decreases the ~~length~~production of ~~stay~~inflammatory cytokines associated with the hyperactive inflammatory response present during COVID-19 infection. Elevated levels of inflammatory cytokines are correlated with COVID-19 severity and may also trigger additional complications including pneumonia, ALI and/or

Table of Contents

ARDS, which is a leading cause of mortality in COVID-19. By targeting and reducing the ~~hospital or~~production of these inflammatory cytokines, Ampion may improve the clinical outcome for patients with COVID-19.

Due to its mode of action, Ampion may be a viable treatment option for those infected with COVID-19 to improve clinical outcomes and decrease the ~~required time on ventilation would not only decrease mortality but also reduce stress on hospital resources, including medical staff, allowing additional~~progression and severity of associated COVID-19 ~~infected patients access to critical~~inflammatory conditions (i.e., COVID-19 pneumonia, ALI, ARDS, and ~~potentially life-saving care.~~

ultimately mortality). Accordingly, Ampion may provide an early intervention option for COVID-19 patients.

As an immunomodulatory agent, we believe that Ampion may be effective in improving the clinical course and outcome of COVID-19 ~~patients requiring oxygen and experiencing respiratory distress, including ARDS and ALI.~~patients.

Ampion Development for Treating COVID-19 Induced Inflammation

~~As reported in~~ ~~The Lancet~~ in February 2020 by Huang et al., patients with coronavirus infection, including COVID-19, present symptoms which are primarily fever, fatigue and dry cough. In some cases, the disease progresses to severe illness, dyspnea and hypoxemia within one week after onset of the disease. These patients with severe illness require oxygen therapy, intensive care, and ventilation as they potentially develop inflammatory complications like ARDS and ALI. ARDS is an inflammatory process, and when secondary to COVID-19, the inflammatory response is exaggerated after being triggered by the initial viral infection. The destructive cycle of inflammation related to the COVID-19 infection may impact the clinical course of patients in several significant and potentially fatal ways, indicating the need for a treatment that can interrupt and/or prevent this inflammatory cascade.

During COVID-19 infection, the activation of the innate immune system leads to a dysregulated or “hyper-inflammatory” response, resulting in the excess release of innate pro-inflammatory cytokines by alveolar macrophages and neutrophils as part of a “cytokine storm”. In humans, the severity of disease, including ARDS, is closely related to increased serum levels of inflammatory cytokines accompanied by a corresponding decrease in anti-inflammatory cytokines. These findings have been published in ~~Cell Host and Microbe~~ ~~in February 2016 by Channappanavar et al. and in~~ ~~The International Journal of Clinical and Experimental Pathology~~ ~~in January 2017 by Yang et al.~~

Ampion is in development as a novel biologic drug that regulates multiple therapeutic targets in the innate immune system responsible for the inflammation, tissue damage and pathogenesis associated with dysregulated immune ~~disorders, such as ARDS. Development of Ampion supports a mechanism~~disorders. Due to its mode of action, ~~as an immunological agent which decreases~~Ampion may be a viable treatment option for those infected with COVID-19 to improve clinical outcomes and slow the ~~production of physiological mediators (e.g.~~progression and severity associated critical COVID-19 inflammatory conditions (i.e., ~~cytokines~~progression to respiratory failure, the need for assisted breathing and chemokines) responsible for inflammation and tissue damage, while simultaneously promoting the production of those mediators required for resolving inflammation and tissue repair. One of the most common and problematic clinical features of ARDS is pulmonary edema, which causes hypoxemia and may result in death. Cellular models treated with Ampion indicate treatment enhances microvascular barrier function in the lung to protect against this facet of ARDS. Ampio is currently working with the FDA to receive authorization to develop Ampion as a potential treatment for complications related to COVID-19 infection.ultimately mortality).

Ampion is currently in development as an IV treatment for COVID-19 patients. In May 2020, we submitted an ~~IND~~Investigational New Drug (“IND”) application for the IV treatment of adults with ~~COVID-19 requiring supplemental oxygen.~~COVID-19. In June 2020, we received FDA agreement to proceed with human trials utilizing an IV Ampion treatment for COVID-19 patients, ~~who require supplemental oxygen,~~ and we commenced the Phase I AP-016 study in July 2020. In September 2020, we ~~completed the AP-016 study and~~announced the results of the AP-016 study, which met its primary endpoint and found Ampion to be safe and well-tolerated with no remarkable difference in the incidence, frequency, and severity of adverse events between IV Ampion and ~~standard of care. These patients will be followed over the upcoming months to complete their safety assessments.~~SOC. Secondary efficacy endpoints from the study suggest Ampion may improve the clinical outcome for patients with COVID-19 as measured by the ordinal scale of clinical improvement as recommended by the WHO, and by the National

~~Table of Contents~~

Early Warning Score, ~~(“NEWS2”),~~ as recommended by the National Institute for Health and Care Excellence ~~(“NICE”)~~ in its guidelines for the management of COVID-19 patients in critical care. Following these results, in December 2020, the Company initiated a multicenter study, the AP-017 study, in the United States and Israel for IV Ampion therapy in patients with COVID-19. In discussions with the FDA for EUA of Ampion for COVID-19 patients, the FDA recommended study updates to protocol AP-017, which were implemented in the study titled “A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Intravenous Ampion in Adult COVID-19 Patients Requiring Oxygen Supplementation”. In June 2021, due to the ongoing turmoil in the region, we decided to pause the AP-017 study in Israel. However, we plan to continue conducting the AP-017 study in the United States. We ~~believe that~~commenced enrollment of the ~~safety and efficacy results could provide~~AP-017 study in the ~~basis for performing a potential Phase II/III trial with IV Ampion.~~United States during the third quarter of 2021.

Ampion is currently in development as an inhaled treatment for COVID-19 patients. In August 2020, we submitted preclinical safety data to support the IND application for inhalation treatment of adults with respiratory distress due to COVID-19 infection. In September 2020, we received FDA agreement to proceed with human trials utilizing ~~inhalation~~inhaled Ampion as a treatment for COVID-19 patients ~~who have respiratory distress,~~ and, in October 2020, we ~~expect~~commenced the AP-014 study. In April 2021, we announced the results from the AP-014 study. The AP-014 study not only met its primary endpoint, but the final data showed a greater improvement in all-cause mortality in COVID-19 patients with Ampion treatment over patients treated using SOC. Specifically, mortality in the SOC group was 24%, while in the group treated with Ampion, mortality was only 5%, representing an almost 80% improvement.

Other key findings from the study continue to ~~commence~~show a positive outcome for patients treated with Ampion including:

●

Patients who received Ampion required less hospitalization time. The average hospital length of stay was four days less for the Ampion group compared to the patients receiving SOC.

●

Patients treated with Ampion were either stable or showed improvement on a scale of clinical improvement compared to patients treated using SOC. By day five, 89% of patients who received Ampion were stable or had improvement compared to 77% of patients who received SOC. This trend in improvement with Ampion treatment is noted as early as day two and continues to day five.

Table of Contents

●

Ampion treatment was safe and well-tolerated in all patients. There were no remarkable adverse events with Ampion treatment, and no drug-related serious adverse events were reported.

In March 2021, we initiated the AP-018 study titled, “A Randomized, Double-Blinded, Placebo-Controlled Phase I ~~AP-014~~Study to Evaluate the Safety and Efficacy of Ampion in Patients with Prolonged Respiratory Symptoms due to COVID-19 (Long-COVID)”. An increasing number of people with COVID-19 are experiencing lingering effects of COVID-19 and continue to have prolonged respiratory complications months after the onset of the disease, also known as PASC, Long-COVID, and/or long-hauler syndrome. This study aims to evaluate the safety of Ampion and the clinical outcomes in patients with Long-COVID. We commenced enrollment of the AP-018 study during the ~~fourth~~third quarter of ~~fiscal 2020.~~2021.

We continue to communicate on a regular basis with the FDA to advance the development of these programs. As an immunomodulatory agent, with anti-inflammatory effects, we believe Ampion may be effective in interrupting the inflammatory cascade associated with COVID-19 and improving the clinical course and outcome for patients.

Due to the global pandemic and the need for new treatments, regulatory authorities are applying emergency approval programs. These programs include the EUA program in the United States. We may seek an EUA from the FDA for the use of Ampion for COVID-19 patients. If we decide to apply for an EUA and it is granted, a separate regulatory process will be needed in order to obtain a full marketing authorization (i.e., non-emergency authorization) for the use of Ampion in COVID-19 patients.

Recent Financing Activities

Information regarding our ~~Recent Financing Activities~~recent financing activities is contained in Note 10 to the Financial Statements.

Known Trends or Future Events; Outlook

We are a pre-revenue stage biopharmaceutical company that has incurred an accumulated deficit of ~~$196.0~~$207.8 million ~~through September~~as of June 30, ~~2020.~~2021. We expect to generate continued operating losses for the foreseeable future as we continue the ongoing development and advancement of immunological-based therapies with the ultimate goal of achieving FDA marketing approval and subsequent commercialization of Ampion for the indications ~~noted above.~~previously discussed. In addition, while working in parallel with the continued advancement of immunology-based therapies for Ampion, we continue to actively explore ~~synergistic~~ licensing and other partnering opportunities with both domestic and global-based organizations in order to further leverage and maximize the value of Ampion to our stockholders.

~~Since June 1, 2020, the Governor of Colorado and the Tri-County Health Department has amended and extended the “Safer at Home and in the Vast, Great Outdoors” order several times,~~We plan to maintain an ongoing dialog with the most recent amendment and extension dated September 19, 2020. However, the order still strongly encourages residents to remain at home. We believe we are considered a “critical business” as defined in the executive order; however, the order’s social distancing requirements have modestly impacted our operations. The extent of such impact continues to be uncertain at this time and will depend on the length of time such restrictions continue.

As increases in COVID-19 cases continue to be reported, we have determined that the AP-013 study will remain paused until the safety of our patients, clinical, and monitoring staff is no longer jeopardized. The continued executive order, shelter-in-place orders and our policies may continue to negatively impact productivity, have adverse effects on the Company’s business, operations, financial condition and results of operations, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our ongoing business operations.

~~While we continue~~FDA to explore all viable options to complete the AP-013 study ~~and evaluate the FDA’s most recent guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were adversely impacted by~~under an amended SPA agreement, as a result of the COVID-19 pandemic itand the related adverse impact on the study. It remains possible that the ongoing COVID-19 pandemic may prevent completion of the study over the near term or at all. Even if the study is completed in the future, the Company anticipates that the impact of the COVID-19 pandemic on the AP-013 study will likely result in a significant delay of its previous projected timeline for submitting a BLA. The spread of COVID-19, which has caused a broad impact globally, may materially affect the Company economically in other ways. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a continued widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access ~~capital.~~capital in a timely and effective manner. In addition, a recession or market correction resulting from the spread of COVID-19 could have a material adverse impact on our ability to raise requisite financing to support our business operations, which would adversely impact the value of our common stock.

As of ~~September~~June 30, ~~2020,~~2021, we had ~~$9.4~~$20.5 million of cash and cash equivalents. ~~In April 2020, we received PPP proceeds of $544,000.~~ During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, we sold ~~23.7~~approximately 5.9 million shares of common stock pursuant to the ATM

~~Table of Contents~~

equity offering program, which yielded gross proceeds of ~~$15.1~~approximately $10.0 million; offset by offering related costs of $873,000. In October 2020, we received additional gross proceeds of $1.0 million from the sale of 1.1 million shares of common stock under the ATM equity offering program; offset by offering related costs of $40,000.$0.4 million. We anticipate the continued use of the ATM equity offering program in a disciplined manner based on near-term liquidity needs and ~~could~~may seek to supplement the funds raised with separate ~~private/~~private or public equity offering(s). Based on our current cash position, projection of operations and expected access to equity financing, we believe we will have sufficient liquidity to fund operations through the ~~third~~fourth quarter of ~~2021.~~2022. This projection is based on many assumptions that may prove to be incorrect. ~~For example, despite~~Despite the ~~historically successful~~prior access and use of the ATM equity offering program due to the inherent uncertainties associated with raising capital in the public markets, our management is unable to conclude that it is probable that future capital will be available to satisfy our future liquidity needs in a manner ~~that will be~~to provide sufficient ongoing liquidity to ~~fund operations.~~the Company, the ATM is not considered to represent a source of committed capital. As such, it is possible that the Company could exhaust its available cash and cash equivalents earlier than presently anticipated. In addition, as the global ~~COVID-19~~ pandemic continues, ~~to rapidly evolve,~~ its effect on the Company’s operations and ability to raise capital through the

Table of Contents

ATM equity offering program, or otherwise, remains ~~highly~~ uncertain and subject to change. These existing and on-going factors continue to raise substantial doubt about our ability to continue as a going concern (see Note 2to the Financial Statements).

Our ~~New Shelf Registration Statement,~~shelf registration statement, which was declared effective by the SEC in May 2020, provides us with the ability to sell up to an aggregate amount of $100.0 million of shares of common stock, preferred stock, debt securities, warrants and units, or any combination thereof, less any sales from the ATM equity offering program that occurred prior to May 6, 2020, which was the effective date of the ~~New Shelf Registration Statement (see~~ ~~Note 10~~ toshelf registration statement. We had $67.3 million remaining under the ~~Financial Statements and the table below for remaining available shares~~shelf registration statement as of ~~September~~June 30, ~~2020).~~2021. However, we cannot be certain that we will be able to secure additional financing or that any funding, or securities offered pursuant to the ~~New Shelf Registration Statement~~shelf registration statement or otherwise, will be adequate to execute our business strategy. Even if we are able to obtain additional financing, such additional financing may be costly and may require us to agree to covenants or other provisions that favor new investors over existing stockholders.


	September 30, 2020		June 30, 2021

Authorized shares		300,000,000		300,000,000

Common stock outstanding		183,938,000		200,070,419
Options outstanding		5,484,000		5,686,989
Warrants outstanding		5,448,000		3,773,598
Reserved for issuance under 2019 Stock and Incentive Plan		8,643,000

Shares reserved for issuance under 2019 Stock and Incentive Plan				7,918,755
Available shares		96,487,000		82,550,239

Average stock price:
Effective registration statement			$	100,000,000
ATM activity (May 6, 2020 - June 30, 2021)				(32,672,000)
Remaining amount on registration statement			$	67,328,000

Average stock price immediately preceding June 30, 2021:
30 day	$	0.84	$	1.78
60 day	$	0.84	$	1.81
90 day	$	0.83	$	1.79

Even though we had approximately 82.6 million shares of common stock authorized and available for future issuance as of June 30, 2021, our ability to raise additional funds by issuing securities pursuant to the current shelf registration statement is limited by the $67.3 million remaining, of which $13.8 million is reserved for the ATM equity offering program. Based on the table above, the average stock price could represent a range of our ability to draw down on the residual shelf capacity. In addition, we, at our discretion, may file a new shelf registration statement to register the issuance and sale of any remaining shares of common stock that are authorized for issuance and/or any other equity or debt securities that may be issued by the Company.

ACCOUNTING POLICIES

Significant Accounting Policies and Estimates

Our financial statements were prepared in accordance with GAAP. The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to recoverability of long-lived assets valuation allowance(s), useful lives of assets and remaining useful lives, accrued compensation, stock compensation, warrant derivative liability, right-of-use asset, lease liability, clinical trial accruals, and the ability for the Company to continue as a going concern. Management bases its estimates and judgments on historical experience and on various

~~Table of Contents~~

other factors that are believed to be reasonable and appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily

Table of Contents

apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates and judgments used by us in applying these critical accounting policies have a significant impact on the results we report in our financial statements. Our significant accounting policies and estimates are included in our ~~2019~~2020 Annual Report. Our significant accounting policies and estimates have not changed substantially from those previously disclosed in our ~~2019~~2020 Annual Report.

Newly Issued Accounting Pronouncements

Information regarding the recently issued accounting standards (adopted and not adopted as of ~~September~~June 30, ~~2020)~~2021) is contained in Note 1 to the Financial Statements.

RESULTS OF OPERATIONS

Results of Operations – ~~September~~June 30, ~~2020~~2021 Compared to ~~September~~June 30, ~~2019~~2020

We recognized a net loss for the three months ended ~~September~~June 30, ~~2020~~2021 (“~~2020~~2021 quarter”) of ~~$3.4~~$3.6 million compared to a net loss of ~~$7.2~~$2.7 million for the three months ended ~~September~~June 30, ~~2019~~2020 (“~~2019~~2020 quarter”). The net loss during the 2021 quarter was primarily attributable to operating expenses of $3.7 million; partially offset by the non-cash derivative gain of $0.1 million. The net loss during the 2020 quarter was primarily attributable to operating expenses of ~~$3.3 million. The net loss during~~$2.6 million and the ~~2019 quarter was primarily attributable to operating expenses of $5.2 million, along with a~~ non-cash derivative loss of ~~$2.1~~$0.7 million; partially offset by the gain realized from the PPP loan forgiveness of $0.5 million. The modest increase in our stock price ~~from $0.39 as of June 30, 2019 to $0.50 as of September 30, 2019~~during the 2020 quarter caused the valuation of the warrant liability to increase resulting in a ~~non-cash~~ derivative loss ~~during the 2019 quarter. The operating~~recorded. Operating expenses ~~for~~increased $1.1 million from the 2020 quarter ~~decreased $1.9 million from~~to the ~~2019~~2021 quarter primarily due to a ~~$1.8~~$1.2 million ~~decrease~~increase in research and development costs, partially offset by a $0.1 million decrease in general and administrative costs, both of which isare further explained below.

We recognized a net loss for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 (“~~2020~~2021 period”) of ~~$11.3~~$7.2 million compared to a net loss of ~~$12.6~~$7.9 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 (“~~2019~~2020 period”). The net loss during the 2021 period was primarily attributable to operating expenses of $7.5 million, partially offset by the non-cash derivative gain of $0.3 million. The modest increase in our stock price during the 2021 period would have normally caused an increase in the warrant liability, resulting in a derivative loss to be recognized. However, during the six months ended June 30, 2021, we had 284,100 investor warrants exercised, which caused the warrant liability to decrease, offsetting the derivative loss from the increase in stock price and resulting in the recognition of a net derivative gain. The net loss during the 2020 period was primarily attributable to operating expenses of ~~$11.9~~$8.6 million, partially offset by the gain realized from the expected PPP loan ~~funding~~forgiveness of ~~$544,000. The net loss during the 2019 period was attributable to operating expenses totaling $11.4~~$0.5 million ~~along with a~~and non-cash derivative ~~loss~~gain of ~~$1.2~~$0.2 million. The ~~increase in our stock price from $0.39 as~~outstanding amount of ~~December 31, 2018~~investor warrants decreased due to ~~$0.50 as of September 30, 2019 caused~~warrant exercises, causing the valuation of the warrant liability to ~~increase resulting~~decrease, which resulted in a non-cash derivative ~~loss~~gain; partially offset by a modest appreciation in our stock price during the ~~2019~~2020 period. The operating expenses ~~increased $500,000~~decreased $1.1 million from the ~~2019~~2020 period to the ~~2020~~2021 period primarily due to a ~~$600,000 increase in general and administrative costs offset by a $100,000~~$0.8 million decrease in research and development costs and a $0.3 million decrease in general and administrative costs, both of which isare further explained below.

3129

Table of Contents

Operating Expenses

Research and Development

Research and development costs (benefits) are summarized as follows and ~~excludes~~exclude an allocation of general and administrative expenses:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Clinical trial and sponsored research expenses	$	272,000	$	2,141,000	$	3,201,000	$	2,986,000	$	808,000	$	(82,000)	$	1,575,000	$	2,928,000
Salaries and benefits		611,000		621,000		1,960,000		1,990,000		613,000		652,000		1,235,000		1,349,000
Depreciation		291,000		312,000		877,000		923,000		268,000		293,000		557,000		586,000
Laboratory										266,000		95,000		381,000		187,000
Operations / manufacturing		235,000		45,000		336,000		303,000		228,000		67,000		617,000		101,000
Laboratory		68,000		135,000		255,000		404,000
Professional fees										72,000		16,000		107,000		41,000
Equipment rental and repair										11,000		11,000		44,000		33,000
Regulatory / FDA										7,000		55,000		6,000		77,000
Stock-based compensation		72,000		46,000		142,000		77,000		—		11,000		46,000		71,000
Regulatory / FDA		60,000		48,000		137,000		212,000
Equipment rental and repair		36,000		52,000		68,000		100,000
Professional fees		10,000		28,000		51,000		134,000
Total research and development	$	1,655,000	$	3,428,000	$	7,027,000	$	7,129,000	$	2,273,000	$	1,118,000	$	4,568,000	$	5,373,000

~~2020~~2021 Quarter Compared to ~~2019~~2020 Quarter

Research and development costs ~~decreased~~increased by approximately ~~$1.8~~$1.2 million, or ~~51.7%~~103%, for the ~~2020~~2021 quarter compared to the ~~2019~~2020 quarter. Research and development costs with variances above $75,000 and 10% compared with the previous quarter are further explained below.

Clinical trial and sponsored research expenses

The clinical trial and sponsored research expenses ~~decreased $1.9~~increased by approximately $0.9 million, or ~~87.3%~~1,085%, ~~for~~primarily due to the initiation of the AP-013 study database contract in December 2020 ~~quarter compared with~~to ensure the ~~2019 quarter as~~validity and accuracy of the study data prior to submission to the FDA. It is important to note that the AP-013 study was paused in April 2020 ~~due to stay-at-home mandate(s) issued by state~~ and ~~federal governments in response to~~remains paused through the ~~pandemic and travel restrictions implemented by~~current period as a result of the ~~CRO.~~pandemic. During the ~~2019~~2020 quarter, we reviewed the AP-013 study was in the initial enrollment phase with the cost reflective of the acceleration of enrollment of sites and patients, which continued on a normalized run rate through first quarter of 2020. Recently, the FDA has provided guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were paused and, as such, adversely impacted by the pandemic. We are carefully reviewing this guidance and plan to submit a proposal to the FDA during the fourth quarter of fiscal 2020 to maintain the SPAtrial accrual assumptions for the AP-013 study and ~~to determine~~adjusted those assumptions accordingly based on discussions with the ~~pathway for completing~~CRO, resulting in a favorable accrual adjustment of $0.5 million. In addition, during the ~~study and filing~~2021 quarter, we incurred costs associated with the ~~BLA. The decrease in expenses related~~various COVID-19 studies of $0.4 million, all of which were initiated subsequent to the ~~AP-013 study was slightly offset by~~2020 quarter.

Laboratory

Laboratory expenses ~~incurred~~increased $171,000, or 180%, for the ~~inhaled~~2021 quarter compared with the 2020 quarter as a result of continued effort and incremental spend associated with research and discovery searching for novel applications to further leverage the Ampion ~~safety study and the AP-016 (IV) study. We expect clinical trial and sponsored research expenses to increase during the fourth quarter of fiscal 2020 due to the AP-014 (inhaled) study.~~platform technology.

Operations / manufacturing

Operations / manufacturing expenses increased ~~$190,000,~~$161,000, or ~~422.2%~~240%, for the ~~2020~~2021 quarter compared with the ~~2019~~2020 quarter as a result of the manufacturing team produced intravenous Ampion for the AP-016 study. In addition, during the 2020 quarter, the FDA granted the Company an IND for inhaled Ampion and the manufacturing team incurred costs associated with producing vialscurrent period production of ~~Ampion~~clinical trial products to be utilized in the ~~AP-014 study.~~current and upcoming clinical trials.

~~2020~~2021 Period Compared to ~~2019~~2020 Period

Research and development costs decreased by approximately ~~$100,000,~~$0.8 million, or ~~1.4%~~15%, for the ~~2020~~2021 period compared to the ~~2019~~2020 period. Research and development costs with variances above ~~$75,000~~$175,000 and 10% compared with the previous period are further explained below.

3230

Table of Contents

Clinical trial and sponsored research expenses

The clinical trial and sponsored research expenses ~~increased $215,000,~~decreased by approximately $1.4 million, or ~~7.2%~~46%, ~~for the 2020 period compared with the 2019 period. The increase is~~ primarily ~~attributable~~due to the ~~costs~~AP-013 study being temporarily paused in April 2020 and continuing through the current period as a result of the pandemic. The pause of the AP-013 study resulted in a reduction of ongoing patient enrollment and study monitoring expenses totaling $2.8 million; partially offset by $0.4 million of expenses associated with the ~~inhaled Ampion safety study and~~current COVID-19 studies, as well as the AP-016 study that occurred during the 2020 period. As noted above, the AP-013 study was paused in early April 2020 and, as such, we only incurred approximately three months of expenses related to this study during the 2020 period. Similarly, we only incurred approximately three months$1.0 million of expenses related to the AP-013 study ~~during the 2019 period as the study commenced in June 2019. We expect clinical trial and sponsored research expenses to increase during the fourth quarter of fiscal 2020 due~~database contract, which were initiated subsequent to the ~~AP-014 study.~~2020 period.

Laboratory

Laboratory expenses ~~decreased $149,000,~~increased $194,000, or ~~36.9%~~104%, for the ~~2020~~2021 period compared with the ~~2019~~2020 period as ~~we finalized~~ a ~~quality control project related~~result of continued effort and incremental spend associated with searching for novel applications to further leverage the ~~manufacturing of~~ Ampion ~~during the 2019 period.~~platform technology.

~~Professional fees~~Operations / manufacturing

~~Professional fees decreased $83,000,~~Operations / manufacturing expenses increased $516,000, or ~~61.9%~~511%, for the ~~2020 period~~2021 quarter compared with the ~~2019~~2020 quarter as a result of the current period ~~as we finalized a quality control project related~~production of clinical trial products to be utilized in the ~~manufacturing of Ampion during the 2019 period.~~current and upcoming clinical trials.

General and Administrative

General and administrative expenses are summarized as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Professional fees	$	445,000	$	741,000	$	1,798,000	$	1,695,000	$	517,000	$	614,000	$	997,000	$	1,355,000
Insurance		341,000		269,000		933,000		553,000		330,000		319,000		669,000		592,000
Salaries and benefits		236,000		177,000		748,000		794,000		240,000		275,000		477,000		512,000
Stock-based compensation		405,000		229,000		692,000		358,000		67,000		53,000		267,000		286,000
Facilities		121,000		115,000		368,000		376,000		128,000		120,000		256,000		247,000
Director fees		60,000		96,000		203,000		246,000		68,000		60,000		159,000		143,000
Other		32,000		53,000		81,000		116,000		34,000		22,000		71,000		48,000
Travel and meetings		4,000		57,000		65,000		111,000		10,000		16,000		15,000		60,000
Depreciation		3,000		8,000		8,000		52,000		6,000		3,000		12,000		6,000
Total general and administrative	$	1,647,000	$	1,745,000	$	4,896,000	$	4,301,000	$	1,400,000	$	1,482,000	$	2,923,000	$	3,249,000

~~2020~~2021 Quarter Compared to ~~2019~~2020 Quarter

General and administrative costs decreased ~~$98,000,~~$82,000, or ~~5.6%~~6%, for the ~~2020~~2021 quarter compared to the ~~2019~~2020 quarter. General and administrative costs with variances above $75,000 and 10% are further explained below.

Professional fees

Professional fees decreased ~~$296,000,~~$97,000, or ~~39.9%~~16%, for the ~~2020~~2021 quarter compared to the ~~2019~~2020 quarter due primarily ~~due~~ to a decrease in litigation related legal ~~fees as~~costs which are directly attributable to the dismissal of the securities class action ~~was dismissed with prejudice~~ and ~~the plaintiffs did not appeal, therefore, the case is closed. In addition, the~~ derivative cases ~~were dismissed without prejudice~~ during the ~~2020 quarter.~~third quarter of 2020.

~~Stock-based compensation~~2021 Period Compared to 2020 Period

~~Stock-based compensation expense increased $176,000,~~General and administrative costs decreased $326,000, or ~~76.8%~~10%, for the ~~2020 quarter~~2021 period compared to the ~~2019 quarter due to the issuance of stock options to employees~~2020 period. General and ~~modification of stock options previously awarded to non-employee directors during the 2020 quarter.~~administrative costs with variances above $175,000 and 10% are further explained below.

3331

Table of Contents

~~2020 Period Compared to 2019 Period~~

General and administrative costs increased $595,000, or 13.8%, for the 2020 period compared to the 2019 period. General and administrative costs with variances above $75,000 and 10% are explained below.

Professional fees

Professional fees ~~increased $103,000,~~decreased $358,000, or ~~6.1%~~26%, for the ~~2020~~2021 period compared to the ~~2019~~2020 period due primarily ~~due~~ to ~~an increase~~a decrease in litigation related legal ~~fees related~~costs which are directly attributable to ~~litigation and other matters. As noted above,~~the dismissal of the securities class action ~~was dismissed with prejudice~~ and ~~the plaintiffs did not appeal, therefore, the case is closed. In addition, the~~ derivative cases ~~were dismissed without prejudice~~ during the ~~2020 period. In addition, we incurred expenses related to a strategic advisory firm to evaluate strategic opportunities for the Company and which was initiated in August 2019.~~third quarter of 2020.

~~Insurance~~

Insurance expense increased $380,000, or 68.7%, for the 2020 period compared to the 2019 period. The increase is primarily due to an increase in our D&O insurance premiums covering our prior two policy renewals in June 2019 and June 2020, which were significantly higher than the policy renewal in June 2018 resulting in lower expense for the 2019 period. The consecutive year increases are consistent with increases experienced by the overall market for public biopharmaceutical companies.

~~Stock-based compensation~~

Stock-based compensation increased $334,000, or 93.3%, for the 2020 period compared to the 2019 period due to the issuance of stock options to employees and modification of stock options previously awarded to non-employee directors during the 2020 period.

Cash Flows

Cash flows for the respective periods are as follows:


	Nine Months Ended September 30,				Six Months Ended June 30,
	2020		2019		2021		2020
Net cash used in operating activities	$	(11,849,000)	$	(10,632,000)	$	(6,475,000)	$	(9,143,000)
Net cash used in investing activities		(48,000)		(14,000)		(81,000)		—
Net cash provided by financing activities		14,726,000		11,105,000		9,759,000		7,453,000
Net change in cash and cash equivalents	$	2,829,000	$	459,000	$	3,203,000	$	(1,690,000)

Net Cash Used in Operating Activities

During the ~~nine~~six months ended ~~September~~June 30, 2021, our operating activities used approximately $6.5 million in cash and cash equivalents, which was less than our reported net loss of $7.2 million. The difference is primarily a result of periodic non-cash charges related to depreciation and amortization, stock-based compensation and issuance of common stock for services totaling $0.9 million and an increase in working capital of $0.1 million; partially off-set by the non-cash adjustment for the warrant derivative gain totaling $0.3 million.

During the six months ended June 30, 2020, our operating activities used approximately ~~$11.9~~$9.1 million in cash and cash equivalents, which was more than our net loss of ~~$11.3~~$7.9 million primarily as a result of a decrease in working capital, excluding cash and cash equivalents, totaling ~~$1.7~~$1.5 million and non-cash ~~adjustment~~adjustments for the warrant derivative and PPP funding totaling $0.7 million; partially off-set by non-cash charges related to depreciation and amortization, stock-based compensation and issuance of common stock for services totaling ~~$1.8~~$1.0 million.

During the nine months ended September 30, 2019, our operating activities used approximately $10.6 million in cash, which was less than our net loss of $12.6 million, primarily as a result of the non-cash adjustment for the warrant derivative of $1.2 million and non-cash charges related to depreciation and amortization, stock-based compensation and issuance of common stock for services totaling $1.4 million; partially off-set by a decrease in working capital, excluding cash and cash equivalents totaling $600,000.

~~Table of Contents~~

Net Cash Used in Investing Activities

During the ~~nine~~six months ended ~~September~~June 30, ~~2020, $48,000~~2021, $81,000 in cash and cash equivalents was used to acquire manufacturing machinery and equipment.

During the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, $0 in cash and cash equivalents was used to acquire ~~$14,000 of~~ manufacturing machinery and equipment.

Net Cash Provided by Financing Activities

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, we received gross proceeds of ~~$15.1~~approximately $10.0 million from the sale of ~~23.7~~approximately 5.9 million shares of common stock pursuant to the ~~Sales Agreement,~~ATM equity offering program, which was partially offset by ~~offering related~~offering-related costs of ~~$873,000. We~~$0.4 million. In addition, we also received proceeds of ~~$465,000~~$234,000 from investor warrant exercises and stock option exercises.

During the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, we received gross proceeds of ~~$12.0~~$7.9 million from the sale of ~~30.0~~14.3 million shares of common stock ~~in a public~~pursuant to the ATM equity offering program, which was partially offset by ~~offering~~offering-related costs of ~~$1.2~~$0.6 million. WeIn addition, we also received proceeds of ~~$350,000~~$100,000 from investor warrant exercises.

Table of Contents

Liquidity and Capital Resources

WeSince inception, we have not generated operating revenue or profits. ~~Our primary activities since inception~~Over this period, we have ~~been~~continued to be focused on research and clinical development activities for the advancement of Ampion towards multiple BLA ~~submissions,~~submissions; all of which has required raising a substantial amount of capital. As of ~~September~~June 30, ~~2020,~~2021, we do not have a fixed and determinable committed source of liquidity to meet our expected obligations ~~for~~over the next twelve months. Specifically, we had ~~$9.4~~$20.5 million of cash and cash equivalents as of ~~September~~June 30, ~~2020. We anticipate using~~2021.

Although the ATM and/or other equity ~~offering program to raise funds in the near term and could supplement the funds raised with separate private/public equity offering(s). Based~~financing programs are not committed sources of liquidity, based on ~~our current cash position, projection of operations and~~ expected access to the ATM, consistent with previous periods, and potential for future equity financing programs, we ~~believe~~project that we will have sufficient liquidity to fund operations through ~~the third~~fourth quarter of ~~2021.~~2022. Our projection is based on many assumptions that may prove to be incorrect. For example, despite the historically successful use of the ATM equity offering program, due to the inherent uncertainties associated with raising capital in the public markets and the fact that the ATM equity offering program is not deemed a fixed and determinable committed source of liquidity, our management is unable to conclude that it is probable that future capital will be available to satisfy our future liquidity needs in a manner that will be sufficient to fund operations. As such, it is possible that we could exhaust our available cash and cash equivalents earlier than presently anticipated. In addition, as the global ~~COVID-19~~ pandemic continues ~~to rapidly evolve,~~in an unpredictable manner, its effect on our business ~~financial condition~~operations and ~~results of operations are~~ability to raise capital through the ATM equity offering, or otherwise, remains highly uncertain and subject to change. WeWhile we believe the studies currently being conducted will be successful, we anticipate that we will seek to raise additional capital investments in both the near and long-term to enable us to primarily support (i) clinical development of Ampion, (ii) BLA preparation and submission, (iii) existing base business operations and (iv) commercial development activities for Ampion. We intend to continue our close evaluation of the overall capital markets to determine the appropriate timing and funding level for any such capital raising ~~activity,~~activities, which will primarily depend on our stock price and existing market conditions relative to our need for funds at such time.

The audit report on our financial statements for the fiscal year ended December 31, ~~2019 contained~~2020 contains an explanatory paragraph indicating that there was substantial doubt about our ability continue as a going concern. In order to address the going concern, we have prepared a projection through ~~September 30, 2021.~~August 31, 2022. Our projection reflects cash requirements for fixed, recurring base business expenses such as payroll, legal and accounting, patents and overhead, and incremental costs supporting our current and projected clinical development programs. We continue to closely monitor and assess the impact of the COVID-19 pandemic, including the increase in COVID-19 cases in the United States, on the AP-013 study, and, as such, we are not currently in a position to project the required liquidity needs for completion of the study. Accordingly, we believe that it will be necessary to continue the disciplined raise of additional capital and/or enter into licensing or collaboration agreements to fund the further development and regulatory activities that we plan to conduct.

In May 2020, the ~~New Shelf Registration Statement~~shelf registration statement was declared effective by the SEC and, as of ~~September~~June 30, ~~2020,~~2021, we ~~have~~had approximately ~~$88.4~~$67.3 million available for issuance under the ~~New Shelf Registration Statement~~shelf registration statement with ~~96.5~~approximately 82.6 million authorized shares of common stock remaining available for ~~issuance (see~~ ~~Note 10~~ ~~of the Financial Statements). At this time, we expect to satisfy our future cash needs through our disciplined use of our ATM equity offering program, which may be supplemented by other~~

~~Table of Contents~~

private or public offerings of securities, option/warrant exercises, debt financings and/or partnering/licensing transactions. The continued volatility in the financial markets has adversely affected the market capitalizations of many pre-revenue stage biopharmaceutical companies, particularly small capitalization companies such as Ampio, and generally has made equity and debt financing difficult to obtain in a manner that is not significantly detrimental to the business and without significant dilution to existing stockholders. This volatility, along with the COVID-19 pandemic and other factors, may limit our access to additional financing.issuance.

IfIn the event that we ~~cannot~~are unable to obtain funding through capital raises and/or partnering/licensing transactions in the future when deemed ~~necessary,~~appropriate, we will likely be required to delay, reduce the scope of or eliminate our development, manufacturing and/or regulatory programs for Ampion and/or our future commercialization efforts and/or suspend operations for a period of time until we are able to secure additional funding. If we are not successful in raising sufficient funds to pay for further development and licensing of Ampion, we may choose to license or otherwise relinquish greater, or all rights to Ampion, at an earlier stage of development or on less favorable terms than we would otherwise choose. This could lead to impairment or other charges, which could materially affect our balance sheet and operating results.

Off Balance Sheet Arrangements

We do not have off-balance sheet arrangements, financings or other relationships with unconsolidated entities or other persons, also known as “variable interest entities”.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Table of Contents

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such terms are defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of senior management, including the CEO and the CFO, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based upon this evaluation, the CEO and the CFO concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Information regarding our Legal Proceedings is contained in Note 13 to the Financial Statements.

~~Table of Contents~~

Item 1A. Risk Factors.

We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this Quarterly Report on Form 10-Q, ~~and the risk factors included below,~~ you should carefully consider the factors in Part I, “Item 1A. Risk Factors” in our ~~2019~~2020 Annual Report ~~as updated by our Quarterly Reports on Form 10-Q~~ and other reports that we have filed with the SEC, which could materially affect our business, financial condition or future results. Except as set forth below, during the period covered by this Quarterly Report on Form 10-Q, there have been no material changes in our risk factors as previously disclosed.

Our ~~business, financial condition and results~~pursuit of ~~operations~~Ampion as a COVID-19 therapeutic treatment is at an early stage. We may be ~~materially adversely affected by global health epidemics, including, but not limited~~unable to produce a

drug that successfully treats the ~~recent COVID-19 pandemic.~~virus in a timely manner, if at all.

~~Outbreaks~~Since June 2020, we have commenced several clinical trials to determine the safety and efficacy for application of ~~epidemic, pandemic~~Ampion (i.e., inhaled and intravenous), as a therapeutic treatment for COVID-19. Our development of a COVID-19 treatment is in its early stages, and we may be unable to produce a drug that successfully treats COVID-19 related illness in a timely manner, if at all. We are also committing financial resources and personnel to the development of these COVID-19 treatments which may cause delays in or ~~contagious diseases such~~otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of COVID-19 as a global health concern. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which our treatments, if developed, may not be partially or fully effective. In addition, conducting a clinical trial of a COVID-19 treatment is challenging in the current environment due to a number of factors, including a large number of competitive clinical trials seeking to enroll COVID-19 patients, the high workload of hospital staff, variability in vaccination rates among the population, mutations of the COVID-19 virus and related illness in certain geographies, and the difficulty of enrolling patients in intensive care or similar environments. These challenges may delay our clinical trials and may increase the costs of, or otherwise adversely affect, our clinical trials which could ~~have an adverse effect on~~materially impact our business, financial condition, and results of operations. In January 2020, the WHO announced a global health emergency because of COVID-19. In March 2020, the WHO declared the outbreak COVID-19, a global pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic has and continues to significantly affect the United States and global economies. The outbreak has and may continue to affect the Company’s operations and those of third parties on which the Company relies, including negatively impacting the conduct of current and projected clinical trials.

More specifically, our AP-013 study has been and may continue to be significantly affected by the COVID-19 pandemic. As a result of the continuation of the pandemic, clinical site monitoring and patient visits may continue to be delayed due to government mandated and/or CRO initiated travel restrictions and prioritization of clinic resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be challenging and adversely impact our clinical trial operations. In April 2020, we paused all ongoing conduct associated with the AP-013 study. Due to the continued steady increase in reported cases, we have determined that the AP-013 study will remain paused. However, the FDA recently provided guidance specifically designed to assist the pharmaceutical industry with viable options for evaluating data from clinical trials which were adversely impacted by the pandemic. We are reviewing this guidance and continue to have ongoing discussions with the CRO to determine the best approach for the AP-013 study.

In addition, we believe Ampion may be able to treat the serious complications related to the COVID-19 outbreak, including the need for supplemental oxygen and the rapid onset of respiratory failure, termed ARDS or ALI, and we are pursuing new studies related to these life-threatening COVID-19 manifestations. Clinical trials for Ampion that address these serious complications could be impacted if the pandemic subsides or if there is not a sufficient number of COVID-19 patients located in the area where we perform clinical trials.

The full extent of potential impacts of the COVID-19 pandemic on our business and product development, including our clinical trials, financial condition and the global economy will depend on future developments, which are highly uncertain and cannot be predicted due to the uncertain nature of the COVID-19 pandemic and its effects, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. These effects could have a material adverse impact on our business, operations, financial condition and results of operations. Existing insurance coverage may not provide protection for all, or any, costs that may arise from all such possible events. We continue to assess the impact of COVID-19 on our business operations, system supports and financial condition, but there can be no assurance that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular.

~~There are no assurances that the PPP loan will be forgivable in whole or in part.~~

In April 2020, the Company received PPP proceeds of $544,000. The PPP loan matures in April 2022 and has an annual interest rate of 1.0%. Payments of principal and interest are deferred until August 2021. Pursuant to Section 1106 of the CARES Act and as amended by Section 3(c) of the Flexibility Act, the Company has applied for and may be granted

3734

Table of Contents

forgiveness for all or a portion of the PPP loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for qualifying expenses, which include payroll costs, rent, and utility costs over the 24-week measurement period following receipt of the loan proceeds.

In October 2020, the Company submitted the PPP loan forgiveness application, which has been approved by the Lender. In accordance with the Flexibility Act, the Lender has 60 days from receipt of the completed application to issue a decision to the SBA. If the Lender determines that the borrower is entitled to forgiveness of some or all of the amount applied for under the statue and applicable regulations, the Lender must request payment from the SBA at the time the Lender issues its decision to the SBA. The SBA will, subject to any SBA review of the loan or loan application, remit the appropriate forgiveness amount to the Lender, plus any interest accrued through the date of payment, not later than 90 days after the Lender issues its decision to the SBA. However, the Company cannot give any assurance that it will obtain forgiveness of the PPP loan in whole or in part.

~~The trading price of the shares of our common stock has been and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses.~~

Our stock price has been and will likely continue to be volatile for the foreseeable future. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In addition, recently the stock market in general and the market for biotechnology companies in particular have experienced heighted volatility due to the continued worldwide spread of COVID-19.

In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies including us following periods of volatility in the market prices of these companies’ and our stock. Such litigation could cause us to incur substantial costs and divert management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

During the three months ended ~~September~~June 30, ~~2020,~~2021, we issued ~~276,000~~29,158 shares of common stock to former placement agents as a result of net exercises of placement agent warrants, with an exercise ~~price of~~prices ranging from $0.50 to $0.76 per share of common stock, where the total number of shares of common stock to be issued ~~was~~were reduced to cover the exercise price. We did not receive any cash related to the exercise of the placement agent warrants.

The issuance of the above securities was exempt from the registration requirements under Rule 4(2) of the Securities Act of 1933, as amended, and/or Rule 506 as promulgated under Regulation D.

Item 3. Defaults Upon Senior Securities.

~~Not Applicable.~~None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

~~Not Applicable.~~

~~Table~~The Board of ~~Contents~~Directors of the Company has set the date of the 2021 Annual Meeting of Stockholders for August 14, 2021 at 9:00 a.m. Mountain Time to be held entirely virtually by means of remote communication. For additional information, please see the Company’s definitive proxy statement which was filed with the SEC on June 30, 2021.

Item 6. Exhibits.

The exhibits listed on the “Exhibit Index” set forth below are filed or furnished with this Quarterly Report on Form 10-Q or incorporated by reference as set forth therein.


Exhibit Number		Description
3.1		Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 ~~to the Company’s Current Report on~~from Registrant’s Form 8-K filed on March 30, 2010).
3.2		Certificate of Amendment to Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.4 ~~to the Company’s Current Report on~~from Registrant’s Form 8-K filed on March 30, 2010).
3.3		Plan of Conversion of Chay Enterprises, Inc. ~~into~~to a Delaware corporation (incorporated by reference to Exhibit 2.1 ~~to the Company’s Current Report on~~from Registrant’s Form 8-K filed on March 30, 2010)..
3.4		Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 ~~to the Company’s Current Report on~~from Registrant’s Form 8-K filed on December 18, 2019).
3.5		Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 ~~to the Company’s Quarterly Report on~~from Registrant’s Form 10-Q filed on November 14, 2018).
~~10.1~~		Amendment No. 3 to Employment Agreement, dated July 13, 2020, between the Company and Daniel Stokely (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 14, 2020).
31.1		Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2		Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certificate of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*#

101		XBRL (eXtensible Business Reporting Language). The following financial statements from Ampio Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~September~~June 30, ~~2020,~~2021, formatted in Inline XBRL: (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations, (iii) the Condensed Statements of Stockholders’ Equity (Deficit), (iv) the Condensed Statements of Cash Flows, and (v) the Notes to Financial Statements.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

# Furnished herewith.

3935

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	AMPIO PHARMACEUTICALS, INC.

	By:	/s/ Michael Macaluso
		Michael Macaluso
		Chairman and Chief Executive Officer
		Date: ~~November 3, 2020~~August 4, 2021

	By:	/s/ Daniel G. Stokely
		Daniel G. Stokely
		Chief Financial Officer and Secretary
		Date: ~~November 3, 2020~~August 4, 2021

4036


		Page
	PART I-FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2421

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3633

Item 4.	Controls and Procedures	3634

	PART II-OTHER INFORMATION

Item 1.	Legal Proceedings	3634

Item 1A.	Risk Factors	3734

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3835

Item 3.	Defaults Upon Senior Securities	3835

Item 4.	Mine Safety Disclosures	3835

Item 5.	Other Information	3835

Item 6.	Exhibits	3935

SIGNATURES		4036


	Estimated	Weighted Average	Net Book Value								Net Book Value
	Useful Lives	Remaining Useful	December 31,						Accumulated		September 30,
	in Years	Lives in Years	2019		Additions		Disposals		Depreciation		2020

Leasehold improvements	10	4	$	2,850,000	$	—	$	—	$	(450,000)	$	2,400,000
Manufacturing facility/clean room	3 - 8	3		1,550,000		9,000		(73,000)		(370,000)		1,116,000
Lab equipment and office furniture	5 - 8	3		348,000		39,000		—		(65,000)		322,000
Fixed assets, net			$	4,748,000	$	48,000	$	(73,000)	$	(885,000)	$	3,838,000


	September 30, 2020

PPP loan proceeds	$	544,000
Qualified expenses eligible for forgiveness		(544,000)
PPP loan balance	$	—


	Total (1)		2020		2021		2022		2023		2024		Thereafter
Key clinical research trial obligations	$	2,915,000	$	675,000	$	2,240,000	$	0	$	0	$	0	$	0
BLA consulting services		1,143,000		—		457,000		686,000		0		0		0
Statistical analysis and programming consulting services		318,000		30,000		288,000		0		0		0		0
Employment agreements		1,478,000		216,000		783,000		466,000		13,000		0		0
Commercial insurance premium financing agreement		721,000		474,000		247,000		0		0		0		0
	$	6,575,000	$	1,395,000	$	4,015,000	$	1,152,000	$	13,000	$	0	$	0


	September 30, 2020

Original contract (based on 724 patients)	$	6,180,000
Amendment to contract (based on 1,034 patients)		4,075,000
Total contract	$	10,255,000

Initial deposit (included in original contract amount)	$	861,000
Amendment to deposit		699,000
Expenses incurred applied to deposit		(1,386,000)
Remaining deposit (applied to future expenses)	$	174,000

Expenses incurred/accrued (includes expenses applied to deposit)	$	8,182,000

Total future commitment	$	2,073,000